Rush System for Health

Consolidated Financial Statements as of and for the Years Ended June 30, 2019 and 2018,
Single Audit Supplementary Report as of and for the Year Ended June 30, 2019, and Independent Auditors’ Report
## TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>INDEPENDENT AUDITORS’ REPORT</td>
<td>1–2</td>
</tr>
<tr>
<td>CONSOLIDATED FINANCIAL STATEMENTS AS OF AND FOR THE</td>
<td></td>
</tr>
<tr>
<td>YEARS ENDED JUNE 30, 2019 AND 2018:</td>
<td></td>
</tr>
<tr>
<td>Balance Sheets</td>
<td>3</td>
</tr>
<tr>
<td>Statements of Operations and Changes in Net Assets</td>
<td>4–5</td>
</tr>
<tr>
<td>Statements of Cash Flows</td>
<td>6</td>
</tr>
<tr>
<td>Notes to Consolidated Financial Statements</td>
<td>7–40</td>
</tr>
<tr>
<td>SUPPLEMENTAL SCHEDULES:</td>
<td>41</td>
</tr>
<tr>
<td>Independent Auditors’ Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <em>Government Auditing Standards</em></td>
<td>42–43</td>
</tr>
<tr>
<td>Schedule of Expenditures of Federal Awards</td>
<td>45–50</td>
</tr>
<tr>
<td>Schedule of Expenditures of State Awards</td>
<td>51</td>
</tr>
<tr>
<td>Notes to the Schedules of Expenditures of Federal Awards and State Awards</td>
<td>52</td>
</tr>
<tr>
<td>Schedule of Findings and Questioned Costs</td>
<td>53–54</td>
</tr>
<tr>
<td>Summary Schedule of Prior Audit Findings</td>
<td>55</td>
</tr>
</tbody>
</table>
INDEPENDENT AUDITORS’ REPORT

To the Board of Trustees of Rush System for Health:

We have audited the accompanying consolidated financial statements of Rush System for Health and its subsidiaries (the “System”), which comprise the consolidated balance sheets as of June 30, 2019 and 2018, and the related consolidated statements of operations, changes in net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

Management’s Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the System’s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the System’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the System as of June 30, 2019 and 2018, and the results of their operations and their cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Changes in Accounting Principle

As discussed in Note 2 to the financial statements, Rush has adopted Accounting Standards Updated No. 2016-14, Not-for-Profit Entities (Topic 958): Presentation of Financial Statements of Not for Profit Entities and ASU No. 2014-09, Revenue from Contracts with Customers, during the year ended June 30, 2019. Our opinion is not modified with respect to this matter.
Other Matters

Other Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards as required by Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audits of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements, or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with Government Auditing Standards, we have also issued our report dated October 25, 2019, on our consideration of Rush’s internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Rush’s internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with Government Auditing Standards in considering Rush’s internal control over financial reporting and compliance.

Deloitte & Touche LLP

October 25, 2019
RUSH SYSTEM FOR HEALTH
CONSOLIDATED BALANCE SHEET
(Dollars in thousands)

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CURRENT ASSETS:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$118,939</td>
<td>$157,303</td>
</tr>
<tr>
<td>Accounts receivable for patient services</td>
<td>393,045</td>
<td>314,771</td>
</tr>
<tr>
<td>Other accounts receivable</td>
<td>78,085</td>
<td>59,464</td>
</tr>
<tr>
<td>Self-insurance trust — current portion</td>
<td>30,629</td>
<td>20,346</td>
</tr>
<tr>
<td>Other current assets</td>
<td>84,543</td>
<td>86,237</td>
</tr>
<tr>
<td>Total current assets</td>
<td>705,241</td>
<td>638,121</td>
</tr>
<tr>
<td><strong>ASSETS LIMITED AS TO USE AND INVESTMENTS:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investments — less current portion</td>
<td>1,181,345</td>
<td>1,141,777</td>
</tr>
<tr>
<td>Limited as to use by donor or time restriction or other</td>
<td>609,603</td>
<td>598,020</td>
</tr>
<tr>
<td>Self-insurance trust — less current portion</td>
<td>126,150</td>
<td>114,617</td>
</tr>
<tr>
<td>Total assets limited as to use and investments</td>
<td>1,917,098</td>
<td>1,854,414</td>
</tr>
<tr>
<td><strong>PROPERTY AND EQUIPMENT — net</strong></td>
<td>1,552,941</td>
<td>1,497,632</td>
</tr>
<tr>
<td><strong>OTHER ASSETS</strong></td>
<td>67,252</td>
<td>54,339</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>$ 4,242,532</td>
<td>$ 4,044,506</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LIABILITIES AND NET ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CURRENT LIABILITIES:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$73,977</td>
<td>$70,752</td>
</tr>
<tr>
<td>Accrued expenses</td>
<td>328,785</td>
<td>308,317</td>
</tr>
<tr>
<td>Estimated third-party settlements payable</td>
<td>187,276</td>
<td>180,107</td>
</tr>
<tr>
<td>Current portion of accrued liability under self-insurance programs</td>
<td>42,474</td>
<td>30,964</td>
</tr>
<tr>
<td>Current portion of long-term debt</td>
<td>14,270</td>
<td>13,156</td>
</tr>
<tr>
<td>Total current liabilities</td>
<td>646,782</td>
<td>603,296</td>
</tr>
<tr>
<td><strong>LONG-TERM LIABILITIES:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accrued liability under self-insurance programs — less current portion</td>
<td>205,771</td>
<td>181,462</td>
</tr>
<tr>
<td>Postretirement and pension benefits</td>
<td>47,724</td>
<td>24,392</td>
</tr>
<tr>
<td>Long-term debt — less current portion</td>
<td>580,252</td>
<td>598,371</td>
</tr>
<tr>
<td>Line of credit</td>
<td>36,500</td>
<td>36,500</td>
</tr>
<tr>
<td>Obligations under capital lease and other financing arrangements</td>
<td>41,770</td>
<td>51,470</td>
</tr>
<tr>
<td>Other long-term liabilities</td>
<td>118,988</td>
<td>118,706</td>
</tr>
<tr>
<td>Total long-term liabilities</td>
<td>1,031,005</td>
<td>1,010,901</td>
</tr>
<tr>
<td>Total liabilities</td>
<td>1,677,787</td>
<td>1,614,197</td>
</tr>
<tr>
<td><strong>NET ASSETS:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Without donor restrictions</td>
<td>1,727,068</td>
<td>1,652,774</td>
</tr>
<tr>
<td>With donor restrictions</td>
<td>837,677</td>
<td>777,535</td>
</tr>
<tr>
<td>Total net assets</td>
<td>2,564,745</td>
<td>2,430,309</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES AND NET ASSETS</strong></td>
<td>$ 4,242,532</td>
<td>$ 4,044,506</td>
</tr>
</tbody>
</table>

See notes to the consolidated financial statements.
RUSH SYSTEM FOR HEALTH
CONSOLIDATED STATEMENTS OF OPERATIONS AND CHANGES IN NET ASSETS
(Dollars in thousands)

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>REVENUE:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient service revenue</td>
<td>$2,315,770</td>
<td>$2,142,514</td>
</tr>
<tr>
<td>Tuition and educational programs revenue</td>
<td>78,129</td>
<td>73,409</td>
</tr>
<tr>
<td>Research revenue and net assets released from restriction and used for research and other operations</td>
<td>135,302</td>
<td>123,440</td>
</tr>
<tr>
<td>Other revenue</td>
<td>82,063</td>
<td>93,274</td>
</tr>
<tr>
<td><strong>Total revenue</strong></td>
<td>$2,611,264</td>
<td>$2,432,637</td>
</tr>
</tbody>
</table>

| **EXPENSES:**          |            |            |
| Salaries, wages and employee benefits | 1,349,233 | 1,249,522 |
| Supplies, utilities and other       | 787,850    | 728,022    |
| Insurance                           | 56,226     | 58,075     |
| Purchased services                  | 209,018    | 151,257    |
| Depreciation and amortization       | 126,899    | 126,847    |
| Interest and fees                   | 24,165     | 24,932     |
| Pension settlement expense          | 23,235     | -          |
| **Total expenses**                 | $2,576,626 | $2,338,655 |

| **OPERATING INCOME**            | 34,638     | 93,982     |

| **NON-OPERATING INCOME**        |            |            |
| Investment income and other — net | 57,413     | 36,464     |
| Contributions without donor restriction | 2,677     | 1,835      |
| Fundraising expenses             | (10,938)   | (10,105)   |
| Change in fair value of interest rate swaps | (3,182)   | 4,402      |
| **Total non-operating income**  | $45,970    | $32,596    |

| **EXCESS OF REVENUE OVER EXPENSES** | $80,608 | $126,578 |

(Continued)
RUSH SYSTEM FOR HEALTH  
CONSOLIDATED STATEMENTS OF OPERATIONS AND CHANGES IN NET ASSETS  
(Dollars in thousands)  

<table>
<thead>
<tr>
<th>For the Years Ended June 30,</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
</table>

**NET ASSETS WITHOUT DONOR RESTRICTIONS**  
Excess of revenue over expenses $ 80,608 $ 126,578  
Net assets released from restrictions used for the purchase of property and equipment 16,804 1,919  
Postretirement related changes other than net periodic postretirement cost (22,270) 18,210  
Other (1,382) 123  
Increase in net assets without donor restrictions 73,760 146,830  

**NET ASSETS WITH DONOR RESTRICTIONS**  
Pledges, contributions and grants 95,867 69,015  
Net assets released from restrictions (61,499) (49,808)  
Net realized and unrealized gains on investments 26,308 48,529  
Increase in net assets with donor restrictions 60,676 67,736  

**INCREASE IN NET ASSETS**  
134,436 214,566  

**NET ASSETS — Beginning of period**  
2,430,309 2,215,743  

**NET ASSETS — End of period**  
$ 2,564,745 $ 2,430,309  

See notes to the consolidated financial statements.  
*(Concluded)*
RUSH SYSTEM FOR HEALTH  
CONSOLIDATED STATEMENTS OF CASH FLOWS  
(Dollars in thousands)

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>OPERATING ACTIVITIES:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increase in net assets</td>
<td>$134,436</td>
<td>$214,566</td>
</tr>
<tr>
<td>Adjustments to reconcile change in net assets to net cash provided by operating activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>126,899</td>
<td>126,847</td>
</tr>
<tr>
<td>Postretirement related changes other than net period postretirement cost</td>
<td>22,270</td>
<td>(18,210)</td>
</tr>
<tr>
<td>Change in fair value of interest rate swaps</td>
<td>3,182</td>
<td>(4,402)</td>
</tr>
<tr>
<td>Net unrealized and realized gains on investments</td>
<td>(82,403)</td>
<td>(80,884)</td>
</tr>
<tr>
<td>Restricted contributions and investment income received</td>
<td>57,840</td>
<td>15,468</td>
</tr>
<tr>
<td>Investment gains on trustee held investments</td>
<td>(64)</td>
<td>(1,812)</td>
</tr>
<tr>
<td>Gain on sale of property and equipment</td>
<td>(1,595)</td>
<td>(20,945)</td>
</tr>
<tr>
<td>Changes in operating assets and liabilities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts receivable for patient services</td>
<td>(78,273)</td>
<td>(23,989)</td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>13,281</td>
<td>37,910</td>
</tr>
<tr>
<td>Estimated third-party settlements payable</td>
<td>7,169</td>
<td>(2,710)</td>
</tr>
<tr>
<td>Pension and postretirement costs</td>
<td>1,062</td>
<td>(25,856)</td>
</tr>
<tr>
<td>Accrued liability under self-insurance programs</td>
<td>36,302</td>
<td>(14,413)</td>
</tr>
<tr>
<td>Other changes in assets and liabilities</td>
<td>(36,767)</td>
<td>(15,013)</td>
</tr>
<tr>
<td>Net cash provided by operating activities</td>
<td>87,659</td>
<td>155,621</td>
</tr>
<tr>
<td><strong>INVESTING ACTIVITIES:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Additions to property and equipment</td>
<td>(187,500)</td>
<td>(190,087)</td>
</tr>
<tr>
<td>Acquisition of physician practices</td>
<td>(632)</td>
<td>-</td>
</tr>
<tr>
<td>Proceeds from sale of property and equipment</td>
<td>2,293</td>
<td>78,624</td>
</tr>
<tr>
<td>Purchase of investments</td>
<td>(2,937,968)</td>
<td>(2,152,407)</td>
</tr>
<tr>
<td>Sale of investments</td>
<td>2,945,975</td>
<td>2,129,306</td>
</tr>
<tr>
<td>Net cash used in investing activities</td>
<td>(177,832)</td>
<td>(134,564)</td>
</tr>
<tr>
<td><strong>FINANCING ACTIVITIES:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proceeds from restricted contributions and investment income</td>
<td>57,840</td>
<td>15,468</td>
</tr>
<tr>
<td>Proceeds from line of credit</td>
<td>-</td>
<td>3,981</td>
</tr>
<tr>
<td>Payment of bond issuance cost</td>
<td>-</td>
<td>(476)</td>
</tr>
<tr>
<td>Payment of long-term debt</td>
<td>(14,090)</td>
<td>(13,343)</td>
</tr>
<tr>
<td>Payment of obligations under capital lease and other financing arrangements</td>
<td>(3,939)</td>
<td>(3,340)</td>
</tr>
<tr>
<td>Proceeds from other financing arrangements</td>
<td>11,998</td>
<td>34,715</td>
</tr>
<tr>
<td>Net cash provided by financing activities</td>
<td>51,809</td>
<td>37,005</td>
</tr>
<tr>
<td><strong>NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</strong></td>
<td>(38,364)</td>
<td>58,062</td>
</tr>
<tr>
<td>CASH AND CASH EQUIVALENTS — Beginning of period</td>
<td>157,303</td>
<td>99,241</td>
</tr>
<tr>
<td><strong>CASH AND CASH EQUIVALENTS — End of period</strong></td>
<td>118,939</td>
<td>$157,303</td>
</tr>
</tbody>
</table>

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash paid for interest</td>
<td>$26,906</td>
<td>$24,659</td>
</tr>
<tr>
<td>Noncash additions to property and equipment</td>
<td>$21,228</td>
<td>$30,027</td>
</tr>
</tbody>
</table>

See notes to consolidated financial statements.
1. ORGANIZATION AND BASIS OF CONSOLIDATION

Rush System for Health ("Rush") is a multihospital system with operations that consist of several diverse activities with a shared mission of patient care, education, research, and community service. Rush consists of an academic medical center, Rush University Medical Center ("RUMC"), and two community hospitals, Rush Copley Medical Center ("RCMC") and Rush Oak Park Hospital ("ROPH"), that each serve distinct markets in the Chicago, Illinois, metropolitan area. RUMC, RCMC and ROPH are all Illinois not-for-profit corporations exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code. Effective March 1, 2017, RUMC and RCMC reorganized their operations under a common corporate parent, Rush System for Health, an Illinois not-for-profit corporation, which is exempt from federal income taxes under Section 501(c)(3) of the Code. Previous to this reorganization, RUMC had an affiliation with RCMC that covers governance and other organization relationships, including an Obligated Group. Pursuant to the Amended and Restated Master Trust Indenture dated February 1, 2015, RUMC and RCMC established an Obligated Group (the "Obligated Group") of which both are members along with ROPH. There were no changes to the Obligated Group members as a result of the reorganization under Rush. RUMC, ROPH and RCMC are jointly and severally liable for certain debts issued through the Illinois Finance Authority (IFA) (see Note 9).

Rush University Medical Center

RUMC, the largest member of Rush, is an academic medical center comprising Rush University Hospital (RUH) and Rush University, located in Chicago, Illinois, and ROPH, located in Oak Park, Illinois.

RUH — A 713-licensed bed acute care, rehabilitation and psychiatric hospital in Chicago, Illinois. RUH also includes a faculty practice plan, Rush University Medical Group, which employed 600 physicians as of June 30, 2019.

Rush University — A health sciences university that educates students in health-related fields. This includes Rush Medical College, the College of Nursing, the College of Health Sciences, and the Graduate College. Rush University also includes a research operation with $171,261 and $162,399 in annual research expenditures during fiscal years 2019 and 2018, respectively.

ROPH — A 201-licensed bed acute care, rehabilitation, and skilled nursing hospital located in Oak Park, Illinois, eight miles west of RUH. ROPH includes an employed medical group, which employed 51 physicians as of June 30, 2019. RUMC is the sole corporate member of ROPH.

Rush Copley Medical Center

RCMC is the sole corporate member of Copley Memorial Hospital, Inc., a 210-bed licensed acute care hospital located in Aurora, Illinois, which includes an employed medical group of 95 physicians as of June 30, 2019.

Rush Health

Rush Health is a network of providers whose members include RUH, ROPH, and RCMC. Rush Health has approximately 1,908 physicians and 584 allied health providers who are on the medical staff of the member hospitals. The financial results of Rush Health are not consolidated with the financial results of Rush and are accounted for using the equity method of accounting (see Note 17).
2. **SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**Basis of Presentation**

The accompanying consolidated financial statements have been presented in conformity with accounting principles generally accepted in the United States of America (GAAP).

**Basis of Consolidation**

Included in Rush’s consolidated financial statements are all of its wholly owned or controlled subsidiaries. All significant intercompany transactions have been eliminated in consolidation.

The supplemental consolidating balance sheet information and consolidating statement of operations and changes in net asset information as of and for the year ended June 30, 2019, are presented for the purpose of additional analysis of Rush’s 2019 consolidated financial statements taken as a whole.

**Use of Estimates**

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

**New Accounting Pronouncements**

Effective July 1, 2018, Rush adopted the Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2014-09, *Revenue from Contracts with Customers (Topic 606)*, which outlined a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry specific guidance. ASU 2014-09 also required expanded disclosures regarding an entity’s revenue recognition policies and significant judgments employed in the determination of revenue. The core principle of the revenue model is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU has been applied retrospectively to all periods presented. The adoption of the ASU did not have a material impact on the consolidated financial statements.

Effective July 1, 2018, Rush adopted ASU No. 2018-08, *Clarifying the Scope and Accounting Guidance for Contributions Received and Contributions Made (Topic 958)*. The ASU provides additional guidance on whether a transaction should be accounted for as a contribution or as an exchange transaction under ASU No. 2014-09, as well as additional guidance on conditional contributions. The adoption of the ASU did not have a material impact on the consolidated financial statements.

Effective July 1, 2018, Rush adopted ASU No. 2016-14, *Presentation of Financial Statements of Not-for-Profit Entities*. The ASU required not-for-profit entities to present on the face of the balance sheet and statement of changes in net assets amounts for two classifications of net assets rather than the previous three classifications, and also enhanced several qualitative and quantitative disclosures related to net assets. Rush has elected to apply the practical expedient and not disclose prior year liquidity and availability of resources and functional expenses.

In February 2016, the FASB issued ASU No. 2016-02, *Leases*. The ASU requires lessees to recognize the right-of-use assets and liabilities that arise from all leases with terms greater than twelve months. The ASU also requires repayments of operating and financing leases to be classified as operating or financing activities, respectively, on the statement of cash flows. Rush adopted the ASU effective July 1, 2019 using a modified retrospective approach. On July 1, 2019, the adoption resulted in an increase of $158 million in right-of-use assets and lease liabilities for operating leases. In addition on July 1, 2019, Rush recognized an increase to net assets without donor restrictions of $34,531
from a cumulative effect of change in accounting principle, which was related to the remaining deferred gain on sale of property from a previous sale leaseback transaction.

In March 2017, the FASB issued ASU No. 2017-07, Compensation – Retirement Benefits. The ASU amends the disclosure requirements related to the income statement presentation of the components of net periodic benefit cost for sponsored defined benefit pension and other postretirement plans. The ASU requires entities to disaggregate the current service cost component from other components within the net benefit cost and present it with other current compensation costs on the income statement, as well as present the other components outside of income from operations. Rush adopted the ASU effective July 1, 2019. The adoption did not have a material impact on the consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments, which amends guidance on the classification of certain cash receipts and payments within the statement of cash flows that were previously unclear or in which there were no specific guidelines. Rush was required to adopt this standard effective July 1, 2019, which did not have a material impact on the consolidated financial statements.

In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities. The ASU eliminates the requirement for not-for-profit organizations to disclose fair value information for financial instruments measured at amortized cost. Rush elected to early adopt this part of the ASU in fiscal year 2019, and therefore Rush did not disclose the fair value information for financial information measured at amortized cost. The remaining parts of the ASU are effective for fiscal year 2020.

In January 2017, the FASB issued ASU 2017-04, Intangibles — Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The ASU eliminates Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The ASU also eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. Rush will still have the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. Rush is beginning to assess the impact of the standard, which is required to be implemented in fiscal year 2023.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. The ASU removes, modifies and adds certain disclosure requirements on fair value required by Topic 820. The ASU is not expected to have a material impact on the consolidated financial statements, which is required to be implemented in fiscal year 2021.

In August 2018, The FASB issued ASU No. 2018-14, Compensation-Retirement Benefits-Defined Benefit Plans. The ASU modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The ASU allows entities to remove disclosures over accumulated comprehensive income and certain information about plan assets. The ASU also requires entities to add disclosures over reasons for significant gains and losses affecting the benefit obligation and any explanation for other significant changes in the benefit obligation or plan assets. Rush is beginning to assess the impact of the standard, which is required to be implemented in fiscal year 2021.

**Cash and Cash Equivalents**

Cash and investments having an original maturity of 90 days or less when purchased are considered to be cash and cash equivalents. These securities are so near maturity that they present insignificant risk of changes in value.
Patient Service Revenue and Patient Accounts Receivable

Patient service revenue is reported at the amount that reflects the consideration to which Rush expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payors (including health insurers and governmental programs) and others, and includes variable consideration for retroactive revenue adjustments due to settlement of audits, review and other investigations. Revenue is recognized as performance obligations are satisfied. Performance obligations are determined based on the nature of the services provided by Rush. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected charges. Rush believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients at Rush receiving inpatient acute care services. For outpatient services, the performance obligation is satisfied as the patient simultaneously receives and consumes the benefits provided as the services are performed. In the case of these outpatient services, recognition of the obligation over time yields the same result as recognizing the obligation at a point in time. Rush measures the performance obligation from inpatient admission, or the commencement of an outpatient service, to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge or completion of the outpatient services. For performance obligations satisfied at a point in time, revenue is generally recognized when goods are provided to its patients and customers in a retail setting. In these instances, Rush does not believe it is required to provide additional goods related to that patient. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period. Amounts related to health care services provided to patients which have not been billed and that do not meet the conditions of an unconditional right to payment at the end of the reporting period are contract assets. Contract asset balances consist primarily of health care services provided to patients who are still receiving inpatient care at Rush at the end of the year. Such amounts totaled $18,189 and $18,673 at June 30, 2019 and 2018, respectively, and are included within other current assets.

Rush determines the transaction price based on standard charges for goods and services provided, reduced by explicit price concessions which consist of contractual adjustments provided to third-party payors and discounts provided to uninsured patients in accordance with Rush’s policy as well as implicit price concessions provided to patients. Rush uses the portfolio approach to account for categories of patient contracts as a collective group rather than recognizing revenue on an individual contract basis. The portfolios consist of major payor classes for inpatient revenue and major payor classes and types of services provided for outpatient revenue. Based on historical collection trends and other analysis, Rush believes that revenue recognized by utilizing the portfolio approach approximates the revenue that would have been recognized if an individual contract approach were used.

Consistent with Rush’s mission, care is provided to patients regardless of their ability to pay. Rush provides care without charge or at amounts less than its established rates to patients meeting certain criteria under its charity care policy. Such amounts determined to qualify as charity care are not reported as revenue. Therefore, Rush has determined it has provided implicit price concessions to uninsured patients and patients with other uninsured balances, such as copays and deductibles. The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts Rush expects to collect based on its collection history with those patients. For the years ended June 30, 2019 and 2018, implicit price concessions totaled approximately $79,952 and $81,078, respectively.
Inventory

Medical supplies, pharmaceuticals, and other inventories are stated at the lower of cost or net realizable value and are included in other current assets in the accompanying consolidated balance sheets.

Fair Value of Financial Instruments

Financial instruments consist of cash and cash equivalents, investments, derivative instruments, accounts receivable, accounts payable, accrued expenses, estimated third-party settlements, and debt. The fair value of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, and estimated third-party settlements approximated their financial statement carrying amount as of June 30, 2019 and 2018, because of their short-term maturity. The fair value of the other instruments is disclosed in Notes 6, 9, and 12.

Assets Limited as to Use and Investments

Assets limited as to use consist primarily of investments limited as to use by donors, unconditional promises to contribute, assets held by trustees under debt or other agreements and for self-insurance, and board designated assets set aside for a specified future use. Investments in equity and debt securities with readily determinable fair values are measured at fair value using quoted market prices or model-driven valuations.

Alternative investments consist of limited partnerships that invest primarily in marketable securities (hedge funds), real estate, and limited partnerships that invest in nonmarketable securities (private equity). Investments in hedge funds and private equity funds are generally not marketable and may be divested only at specified times.

Investments in hedge funds are measured at fair market value based on Rush’s interest in the net asset value (NAV) of the respective fund. The estimated valuations of hedge fund investments are subject to uncertainty and could differ had a ready market existed for these investments. Such differences could be material. Real estate investments are carried at amortized cost. Investments in private equity funds entered into on or after July 1, 2012, are measured at fair value based on the estimated fair values of the nonmarketable private equity partnerships in which it invests, which is equivalent to NAV, when Rush’s ownership is minor (less than 5%). The estimated valuations of private equity partnerships are subject to uncertainty and could differ had a ready market existed for these investments. Such differences could be material. Investments in private equity funds entered into during fiscal year 2012 or prior years are reported at cost, adjusted for impairment losses, based on information provided by the respective partnership when Rush’s ownership percentage is minor (less than 5%). Investments in private equity funds where Rush’s ownership percentage is more than minor, but consolidation is not required (5% to 50%), are accounted for on the equity basis. These investments are periodically assessed for impairment. The financial statements of hedge funds and private equity funds are audited annually, generally on December 31. Rush’s risk in alternative investments is limited to its capital investment and any future capital commitments (see Note 5).

Investment income or loss (including interest, dividends, realized and unrealized gains and losses, and changes in cost-based valuations) is reported within excess of revenue over expenses within the accompanying consolidated statements of operations and changes in net assets, net of investment related expenses, unless the income or loss is restricted by donor or interpretation of law. Investment gains and losses on Rush’s endowment and trustee-held funds are recognized within net assets with donor restrictions. Income earned on tax-exempt borrowings for specific construction projects is offset against interest expense capitalized for such projects.

Derivative Instruments

Derivative instruments, specifically interest rate swaps, are recorded in the consolidated balance sheets as either assets or liabilities at their respective fair values. The change in the fair value of derivative instruments is reflected in non-operating income (expense) in the accompanying consolidated statements of operations and changes in net assets. Net cash settlements and payments, representing the realized changes in the fair value of the interest rate swaps, are
included in interest expense in the accompanying consolidated statements of operations and changes in net assets and as operating cash flows in the accompanying consolidated statements of cash flows (see Note 10).

Property and Equipment

Property and equipment are recorded at cost or, if donated, at fair value at the date of receipt. Expenditures that substantially increase the useful life of existing property and equipment are capitalized. Routine maintenance and repairs are expensed as incurred. Depreciation expense, including amortization of capital leased assets, is recognized over the estimated useful lives of the assets using the straight-line method. Buildings and building service equipment assets have an estimated useful life of 10 to 80 years, moveable equipment assets have an estimated useful life of 5 to 10 years, and computer software and hardware assets have an estimated useful life of 3 to 5 years.

Long-Lived Assets and Impairment

Rush carries tangible and intangible long-lived assets, including goodwill. Rush continually evaluates the recoverability of the carrying value of long-lived assets by reviewing long-lived assets for impairment. No asset impairments were recorded during the years ended June 30, 2019 and 2018.

Asset Retirement Obligations

Rush recognizes the fair value of a liability for legal obligations associated with asset retirements in the period in which it is incurred if a reasonable estimate of the fair value of the obligation can be made. When the liability is initially recorded, Rush capitalizes the cost of the asset retirement obligation by increasing the carrying amount of the related long-lived asset. The liability is accreted to its present value each period, and the capitalized cost associated with the retirement obligation is depreciated over the useful life of the related asset. Upon settlement of the obligation, any difference between the cost to settle an asset retirement obligation and the liability recorded is recognized as a gain or loss in the consolidated statements of operations and changes in net assets. Asset retirement obligations are reported in other liabilities in the accompanying consolidated balance sheets and amounted to $22,263 and $21,187 as of June 30, 2019 and 2018, respectively.

Ownership Interests in Other Health-Related Entities

Rush has a majority ownership interest in a number of subsidiaries, which provide outpatient surgical and imaging services. An ownership interest of more than 50% in another health-related entity in which Rush has a controlling interest is consolidated, except for Rush Health as discussed in Note 1. As of June 30, 2019 and 2018, noncontrolling interests in consolidated subsidiaries amounted to $7,953 and $11,545, respectively. The amounts related to noncontrolling interests are recorded in net assets without donor restrictions, and as the amounts are not material, they are not separately presented in the accompanying consolidated financial statements. Rush also has affiliations with and interests in other organizations that are not consolidated. These organizations primarily provide outpatient health care and managed care contracting services. An ownership interest in another health-related entity of at least 20%, but not more than 50%, in which Rush has the ability to exercise significant influence over the operating and financial decisions of the investee, is accounted for on the equity basis (see Note 18), and the income (loss) is reflected in other revenue. An ownership interest in a health-related entity of less than 20%, in which Rush does not have the ability to exercise significant influence over the operating and financial decisions of the investee, is carried at cost or estimated net realizable value and reported within other assets, which is not material to the consolidated financial statements. Effective April 1, 2019, Rush’s ownership interest in the Rush Oak Brook Surgery Center joint venture was decreased from 50% to 25%. As a result the joint venture is no longer consolidated within the accompanying consolidated balance sheet and is now recorded using the equity method. Total assets of $13,935, total liabilities of $15,197 and total net assets of $(1,262) were removed from the consolidated balance sheet on the date of the ownership change.
Deferred Financing Costs

Debt issuance costs, net of amortization computed on the effective interest basis over the life of the related debt, are reported within long-term debt in the consolidated balance sheets. Unamortized debt issuance costs amounted to $3,827 and $4,606 as of June 30, 2019 and 2018, respectively.

Other Assets

Other assets include investments in joint ventures accounted for on the equity basis, goodwill, insurance recoveries and other intangible assets. Rush reviews goodwill for impairment annually; no impairment was recorded for the fiscal years ended June 30, 2019 and 2018.

Other Long-term Liabilities

Other long-term liabilities include asset retirement obligations, employee benefit plan liabilities for certain defined contribution and supplemental retirement plans other than defined benefit pension plans (see Note 12), liabilities for derivative instruments, and other long-term obligations.

Net Assets

Net assets are classified based on the existence or absence of donor or grantor imposed restrictions. Accordingly, net assets and changes therein are classified and reported as follows:

Net Assets Without Donor Restrictions — Net assets without donor restrictions are resources available to support operations. The only limits on the use of these assets are the broad limits resulting from the nature of the organization, the environment in which it operates, the purposes specified in its corporate documents and its application for tax-exempt status, and any limits resulting from contractual agreements with creditors and others that are entered into in the course of business. The net assets without donor restrictions of the Corporation are primarily derived from annual excess of revenue over expenses and net assets released from donor restrictions for operations. Voluntary resolutions by the Board to designate a portion of its net assets without donor restrictions for specific purposes are presented as board-designated. Because these designations are voluntary and may be reversed by the Board at any time, board-designated net assets are included under the caption “without donor restriction”.

Net Assets With Donor Restrictions — Net assets with donor restrictions are resources that are restricted by a donor for use for a particular purpose or in a particular future period. Some donor-imposed restrictions are temporary in nature, and the restriction will expire when the resources are used in accordance with the donor’s instructions or when the stipulated time has passed. Other donor-imposed restrictions are perpetual in nature, whereby the organization must continue to use the resources in accordance with the donor’s instructions.

Contributions

Unconditional contributions and promises to contribute cash and other assets (pledge receivable) are reported at fair value at the date the promise is received. Fair value is estimated as the net present value of the estimated future cash flows of such awards. Estimated future cash flows due after one year are discounted using interest rates commensurate with the time value of money concept. Net unconditional promises to contribute are reported in assets limited as to use by donor or time restriction in the accompanying consolidated balance sheets and amounted to $26,399 and $27,891 as of June 30, 2019 and 2018, respectively (see Note 15).

Conditional contributions are similarly reported at fair value when the conditions have been substantially met. Contributions are conditional when there are barriers that Rush must overcome to be entitled to the funds. Rush has received approximately $105,405 of conditional contributions whose conditions have not been substantially met as of June 30, 2019. Of this amount, approximately $79,113 relates to federal, state and local grant awards where Rush expects to meet the condition of incurring allowable expenditures under the various grants within the next twelve
months. Another $26,292 is related to awards from foundations and other not-for-profit organizations where Rush expects to recognize the contribution once the conditions have been met.

Unconditional contributions and conditional contributions whose conditions have been substantially met are reported as net assets with donor restrictions if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, the restricted net assets are released as net assets without restrictions and reported in the consolidated statements of operations as other revenue (if time restricted or restricted for operating purposes) or reported in the consolidated statements of changes in net assets as net assets released from restrictions used for purchase of property and equipment (if restricted for capital acquisitions). Donor-restricted contributions for operating purposes whose restrictions are met within the same year as either received or the same year as the condition is substantially met are reported as other revenue in the accompanying consolidated statements of operations and changes in net assets.

Rush is the beneficiary of several split-interest agreements, primarily perpetual trusts held by others, which are recorded in assets limited as to use within the accompanying consolidated balance sheets. Rush recognizes its interest in these trusts based on either Rush’s percentage of the fair value of the trust assets or the present value of expected future cash flows to be received from the trusts, as appropriate, based on each trust arrangement.

Excess of Revenue over Expenses

The consolidated statements of operations and changes in net assets include excess of revenue over expenses as a performance indicator. Excess of revenue over expenses includes all changes in net assets without donor restrictions, net of investment related expenses, except for contributions of (and assets released from donor restrictions related to) long-lived assets, and other items that are required by GAAP to be reported separately (such as extraordinary items, the effect of discontinued operations, postretirement-related changes other than net periodic postretirement costs, and the cumulative effect of changes in accounting principle).

Non-Operating Income (Expense)

Non-operating income (expense) includes items not directly associated with patient care or other core operations of Rush. Non-operating income (expense) consists primarily of investment returns without donor restrictions, endowment investment income appropriated for use, the difference between total investment return and amount allocated to operations for investments designated for self-insurance programs, investment income or loss (including interest, dividends, and realized and unrealized gains and losses), net of investment related expenses, on all other investments unless restricted by donor or interpretation of law, changes in the fair value of interest rate swaps, losses on extinguishment of debt, contributions without donor restrictions, and fundraising expenses.

Consideration of Events Subsequent to the Consolidated Balance Sheet Date

Rush has evaluated events occurring subsequent to the consolidated balance sheet date through October 25, 2019, the date the consolidated financial statements were available to be issued. There were no significant subsequent events through this date, with the exception of the adoption of ASU 2016-02, Leases and ASU 2017-07, Compensation — Retirement Benefits, the issuance of long-term debt and subsequent payoff of the outstanding line of credit (see Note 9), and the corporate restructuring of Rush Health. Effective August 12, 2019, Rush became the sole corporate member of Rush Health.
3. PATIENT SERVICE REVENUE

The mix of patient service revenue, recognized during the years ended June 30, 2019 and 2018, by major payor source and by lines of business, was as follows:

<table>
<thead>
<tr>
<th></th>
<th>RUH</th>
<th>ROPH</th>
<th>RCMC</th>
<th>Physician Groups</th>
<th>Clinical Joint Ventures &amp; Other</th>
<th>Total</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicare</td>
<td>$356,835</td>
<td>$35,251</td>
<td>$51,715</td>
<td>$13,552</td>
<td>$528,502</td>
<td>22.8%</td>
<td></td>
</tr>
<tr>
<td>Medicare Managed Care</td>
<td>61,079</td>
<td>7,900</td>
<td>-</td>
<td>-</td>
<td>89,934</td>
<td>3.6%</td>
<td></td>
</tr>
<tr>
<td>Medicaid</td>
<td>71,238</td>
<td>4,582</td>
<td>2,347</td>
<td>-</td>
<td>114,136</td>
<td>4.6%</td>
<td></td>
</tr>
<tr>
<td>Medicaid Managed Care</td>
<td>147,254</td>
<td>27,610</td>
<td>-</td>
<td>-</td>
<td>218,699</td>
<td>8.9%</td>
<td></td>
</tr>
<tr>
<td>Managed Care</td>
<td>235,722</td>
<td>68,240</td>
<td>20,556</td>
<td>-</td>
<td>445,060</td>
<td>19.2%</td>
<td></td>
</tr>
<tr>
<td>Blue Cross</td>
<td>479,360</td>
<td>52,566</td>
<td>19,843</td>
<td>-</td>
<td>669,292</td>
<td>28.9%</td>
<td></td>
</tr>
<tr>
<td>Commercial, Self-Pay and Other</td>
<td>158,919</td>
<td>33,031</td>
<td>12,362</td>
<td>-</td>
<td>224,312</td>
<td>9.5%</td>
<td></td>
</tr>
<tr>
<td><strong>Revenue</strong></td>
<td>$1,510,407</td>
<td>$245,263</td>
<td>$79,530</td>
<td>$2,315,770</td>
<td></td>
<td>100.0%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>RUH</th>
<th>ROPH</th>
<th>RCMC</th>
<th>Physician Groups</th>
<th>Clinical Joint Ventures &amp; Other</th>
<th>Total</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicare</td>
<td>$334,316</td>
<td>$34,106</td>
<td>$66,760</td>
<td>$48,240</td>
<td>$493,644</td>
<td>23.0%</td>
<td></td>
</tr>
<tr>
<td>Medicare Managed Care</td>
<td>54,468</td>
<td>9,416</td>
<td>-</td>
<td>8</td>
<td>63,884</td>
<td>2.7%</td>
<td></td>
</tr>
<tr>
<td>Medicaid</td>
<td>78,927</td>
<td>3,809</td>
<td>1,511</td>
<td>123,641</td>
<td></td>
<td>5.4%</td>
<td></td>
</tr>
<tr>
<td>Medicaid Managed Care</td>
<td>132,588</td>
<td>16,977</td>
<td>6,998</td>
<td>188,224</td>
<td></td>
<td>8.2%</td>
<td></td>
</tr>
<tr>
<td>Managed Care</td>
<td>232,876</td>
<td>59,966</td>
<td>15,526</td>
<td>419,486</td>
<td></td>
<td>19.5%</td>
<td></td>
</tr>
<tr>
<td>Blue Cross</td>
<td>435,963</td>
<td>61,165</td>
<td>17,242</td>
<td>611,615</td>
<td></td>
<td>28.5%</td>
<td></td>
</tr>
<tr>
<td>Commercial, Self-Pay and Other</td>
<td>136,961</td>
<td>36,598</td>
<td>9,870</td>
<td>218,430</td>
<td></td>
<td>10.1%</td>
<td></td>
</tr>
<tr>
<td><strong>Revenue</strong></td>
<td>$1,406,099</td>
<td>$225,299</td>
<td>$61,377</td>
<td>$2,142,514</td>
<td></td>
<td>100.0%</td>
<td></td>
</tr>
</tbody>
</table>

Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows:

**Medicare and Medicare Managed Care:** Certain inpatient acute care services are paid at prospectively determined rates per discharge based on clinical, diagnostic and other factors. Certain services are paid based on cost-reimbursement methodologies subject to certain limits. Physician services are paid based upon established fee schedules. Outpatient services are paid using prospectively determined rates.

**Medicaid and Medicaid Managed Care:** Medicaid services are generally paid at prospectively determined rates per discharge, per occasion of service.

**Blue Cross, Managed Care, Commercial and Other:** Payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations provide for payment using prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates.

The health care industry is subject to numerous laws and regulations of federal, state, and local governments. Compliance with these laws and regulations, specifically those relating to the Medicare and Medicaid programs, can be subject to review and interpretation, as well as regulatory actions unknown and unasserted at this time. Federal government activity continues with respect to investigations and allegations concerning possible violations of...
regulations by health care providers, which could result in the imposition of significant fines and penalties, as well as significant repayment of previously billed and collected revenues from patient services. Management believes that Rush is in substantial compliance with current laws and regulations.

Laws and regulations governing payment programs are complex and subject to interpretation. Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care using the most likely outcome method. These settlements are estimated based on the terms of the payment agreements with the payor, correspondence from the payor and historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as new information becomes available or as years are settled or are no longer subject to such audits, reviews and investigations. As a result, there is a reasonable possibility that recorded estimated third-party settlements could change by a material amount.

Rush has filed formal appeals relating to the settlement of certain prior-year Medicare cost reports. The outcome of such appeals cannot be determined at this time. Any resulting gains will be recognized in the consolidated statements of operations and changes in net assets when realized.

4. CHARITY CARE

Rush has an established charity care policy and maintains records to identify and monitor the level of charity care it provides. RUMC provides free care to all patients whose family income is 300% of the federal poverty level or less, and an additional discount is available to all patients with family income up to 400% of the federal poverty level. All uninsured patients receive a tiered discount regardless of their ability to pay. These discounts apply to patients with family income ranging from 301% to 1,000% of the federal poverty level, with discounts ranging from 33% to 68%. In addition, any uninsured patient with family income over 1,000% of the federal poverty level would still receive a 33% discount. RCMC provides free care to all patients who apply and support income and asset levels of less than 300% of the current-year poverty level and a 30% discount to all uninsured patients regardless of ability to pay, and discounts balances to patients under 600% of the poverty level. Interest-free payment plans are also provided. Charity care includes the estimated cost of unreimbursed services provided and supplies furnished under its charity care policy and the excess of cost over reimbursement for Medicaid patients. The estimated cost of charity care provided is determined using a ratio of cost to gross charges and multiplying that ratio by the gross unreimbursed charges associated with providing care to charity patients.

In December 2008, the Centers for Medicare and Medicaid Services approved the Illinois Hospital Assessment Program (the “Program”) to improve Medicaid reimbursement for Illinois hospitals. This Program increased net patient service revenue in the form of additional Medicaid payments and increased supplies, utilities, and other expense through a tax assessment from the State of Illinois. In fiscal year 2014, the State of Illinois approved a new enhanced assessment program providing additional funding to Rush. The net benefit to Rush from the Program was $42,267 and $56,284 during the years ended June 30, 2019 and 2018, respectively. For the years ended June 30, 2019 and 2018, the Medicaid payment of $105,985 and $110,409 was included in patient service revenue, representing 5% of the patient service revenue for fiscal years 2019 and 2018, respectively, and the tax assessment of $63,718 and $54,125, respectively, was included in supplies, utilities, and other expenses within the consolidated statements of operations and changes in net assets. The State of the Illinois and the Centers for Medicare and Medicaid Services (CMS) has approved a redesign of the Hospital Assessment program effective July 1, 2018. The redesign did not have a material impact on the RSH.
The following table presents the level of charity care and Medicaid provided for the years ended June 30, 2019 and 2018:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Excess of allocated cost over reimbursement for services provided to hospital Medicaid patients—net of net benefit under the Program</td>
<td>$141,528</td>
<td>$104,515</td>
</tr>
<tr>
<td>Estimated costs and expenses incurred to provide charity care in the hospitals</td>
<td>26,968</td>
<td>33,877</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$168,496</strong></td>
<td><strong>$138,392</strong></td>
</tr>
</tbody>
</table>

Beyond the cost to provide charity care and unreimbursed services to hospital Medicaid patients, Rush also provides substantial additional benefits to the community, including educating future health care providers, supporting research into new treatments for disease, and providing subsidized medical services in response to community and health care needs, as well as other volunteer services. These community services are provided free of charge or at a fee below the cost of providing them.

5. **ASSETS LIMITED AS TO USE AND INVESTMENTS**

Assets limited as to use and investments consist primarily of marketable equity and debt securities, which are held in investment pools to satisfy the investment objectives for which the assets are held or to satisfy donor restrictions. Rush also holds certain investments in alternative investments consisting of hedge funds, real estate investments, private equity funds, and private debt (see Note 2). Assets limited as to use by donor or time restriction also include unconditional promises to contribute (see Note 15).

Following is a summary of the composition of assets limited as to use and investments as of June 30, 2019 and 2018:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marketable securities and short-term investments</td>
<td>$15,108</td>
<td>$22,963</td>
</tr>
<tr>
<td>Fixed income securities</td>
<td>505,350</td>
<td>485,800</td>
</tr>
<tr>
<td>Public equity securities</td>
<td>235,884</td>
<td>218,261</td>
</tr>
<tr>
<td>Fund investments (mutual/commingled)</td>
<td>943,835</td>
<td>901,009</td>
</tr>
<tr>
<td>Alternative investments</td>
<td>230,777</td>
<td>210,140</td>
</tr>
<tr>
<td>Other</td>
<td>(39,365)</td>
<td>(20,978)</td>
</tr>
<tr>
<td><strong>Total assets limited as to use and investments</strong></td>
<td>1,891,589</td>
<td>1,817,195</td>
</tr>
<tr>
<td>Beneficial interest in trusts</td>
<td>29,739</td>
<td>29,675</td>
</tr>
<tr>
<td><strong>Total assets limited as to use and investments—excluding pledges receivable</strong></td>
<td>1,921,328</td>
<td>1,846,870</td>
</tr>
<tr>
<td><strong>Net pledges receivable</strong></td>
<td>26,399</td>
<td>27,891</td>
</tr>
<tr>
<td><strong>Total assets limited as to use and investments</strong></td>
<td>1,947,727</td>
<td>1,874,761</td>
</tr>
<tr>
<td><strong>Less amount reported as current assets</strong></td>
<td>(30,629)</td>
<td>(20,346)</td>
</tr>
<tr>
<td><strong>Assets limited as to use and investments—noncurrent</strong></td>
<td><strong>$1,917,098</strong></td>
<td><strong>$1,854,415</strong></td>
</tr>
</tbody>
</table>

As of June 30, 2019 and 2018, Rush has commitments for additional alternative investments totaling $122,481 and $133,752, respectively.
It is Rush’s intent to maintain a long-term investment portfolio to support its self-insurance program. Accordingly, the total return on investments restricted for the self-insurance program is reported in the component statements of operations and changes in net assets in two income statement line items. The investment return allocated to operations, reported in other revenue, is determined by a formula designed to provide a consistent stream of investment earnings to support the self-insurance provision reported in insurance expense in the accompanying component statements of operations and changes in net assets. This allocated return, 4% for the years ended June 30, 2019 and 2018, approximates the real return that Rush expects to earn on its investments over the long term and totaled $5,731 and $5,419 for the years ended June 30, 2019 and 2018, respectively. The difference between the total investment return and the amount allocated to operations is reported in non-operating income and totaled $2,476 and $428 for the years ended June 30, 2019 and 2018, respectively. There is no guarantee that the investment return expected by management will be realized. For the years ended June 30, 2019 and 2018, the total annual investment return was approximately 5.7% and 4.3%, respectively.

The composition and presentation of investment income and the realized and unrealized gains and losses on all investments, net of investment related expenses, for the years ended June 30, 2019 and 2018, are as follows:

<table>
<thead>
<tr>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interest and dividends</td>
<td>$36,759</td>
</tr>
<tr>
<td>Net realized gains on sales of securities</td>
<td>23,016</td>
</tr>
<tr>
<td>Unrealized gains (losses)—without donor restrictions</td>
<td>30,885</td>
</tr>
<tr>
<td>Unrealized (losses) gains—with donor restrictions</td>
<td>(1,979)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$88,681</strong></td>
</tr>
</tbody>
</table>

Reported as:

<table>
<thead>
<tr>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other operating revenue</td>
<td>$6,044</td>
</tr>
<tr>
<td>Nonoperating income</td>
<td>56,329</td>
</tr>
<tr>
<td>Net assets with donor restrictions - Net realized/unrealized gains on investments</td>
<td>26,308</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$88,681</strong></td>
</tr>
</tbody>
</table>

6. **FAIR VALUE MEASUREMENTS**

As of June 30, 2019 and 2018, Rush held certain assets and liabilities that are required to be measured at fair value on a recurring basis, including marketable securities and short-term investments, certain restricted, trustee and other investments, derivative instruments, and beneficial interests in trusts. Certain alternative investments measured using either the cost or equity method of accounting are excluded from the fair value disclosure provided herein.

**Valuation Principles**

Under FASB Accounting Standard Codification 820, *Fair Value Measurement*, fair value is defined as an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The valuation techniques used to measure fair value are based upon observable and unobservable inputs. Observable inputs generally reflect market data from independent sources and are supported by market activity, while unobservable inputs are generally unsupported by market activity. The three-level valuation hierarchy, which prioritizes the inputs used in measuring fair value of an asset or liability at the measurement date, includes:

*Level 1 inputs* — Quoted prices (unadjusted) for identical assets or liabilities in active markets. Securities typically priced using Level 1 inputs include listed equities and exchange-traded mutual funds.

*Level 2 inputs* — Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in nonactive markets, and model-driven valuations whose inputs are observable for the asset or
liability, either directly or indirectly. Securities typically priced using Level 2 inputs include government bonds (including US treasuries and agencies), corporate and municipal bonds, collateralized obligations, interest rate swaps, commercial paper and currency options.

**Level 3 inputs** — Unobservable inputs for which there is little or no market data available and are based on the reporting entity’s own judgment or estimation of the assumptions that market participants would use in pricing the asset or liability. The fair values for securities typically priced using Level 3 inputs are determined using model-driven techniques, which include option-pricing models, discounted cash flow models, and similar methods. The level 3 classification includes beneficial interests in trusts.

**Fair Value Measurements at the Consolidated Balance Sheet Date**

The following tables present Rush’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2019 and 2018:

<table>
<thead>
<tr>
<th>Fair Value Measurements as of June 30, 2019</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
<th>Valued @ NAV</th>
<th>Total Fair Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marketable securities and short-term investments</td>
<td>$1,790</td>
<td>$219</td>
<td>$ -</td>
<td>$13,050</td>
<td>$15,059</td>
</tr>
<tr>
<td><strong>Fixed Income Securities:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S. Government and Agency securities</td>
<td>-</td>
<td>251,647</td>
<td>-</td>
<td>-</td>
<td>251,647</td>
</tr>
<tr>
<td>Corporate Bonds</td>
<td>-</td>
<td>204,966</td>
<td>-</td>
<td>-</td>
<td>204,966</td>
</tr>
<tr>
<td>Asset Backed Securities and Other</td>
<td>-</td>
<td>48,737</td>
<td>-</td>
<td>-</td>
<td>48,737</td>
</tr>
<tr>
<td><strong>Public Equity Securities</strong></td>
<td>235,884</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>235,884</td>
</tr>
<tr>
<td><strong>Fund Investments (Mutual/Commingled):</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fixed Income Funds</td>
<td>243,188</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>243,188</td>
</tr>
<tr>
<td>Public Equity Funds</td>
<td>225,222</td>
<td>-</td>
<td>-</td>
<td>261,265</td>
<td>486,487</td>
</tr>
<tr>
<td>Multi Asset Class Funds</td>
<td>163,466</td>
<td>-</td>
<td>-</td>
<td>26,819</td>
<td>190,285</td>
</tr>
<tr>
<td><strong>Alternative Investments:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hedge Funds</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>71,226</td>
<td>71,226</td>
</tr>
<tr>
<td>Private Equity Partnerships</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>90,249</td>
<td>90,249</td>
</tr>
<tr>
<td>Private Debt</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>69,302</td>
<td>69,302</td>
</tr>
<tr>
<td><strong>Other:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Derivative Assets</td>
<td>-</td>
<td>416</td>
<td>-</td>
<td>-</td>
<td>416</td>
</tr>
<tr>
<td>Trustee-held Investments</td>
<td>-</td>
<td>-</td>
<td>29,739</td>
<td>-</td>
<td>29,739</td>
</tr>
<tr>
<td>Pending Transactions</td>
<td>-</td>
<td>(65,194)</td>
<td>-</td>
<td>-</td>
<td>(65,194)</td>
</tr>
<tr>
<td><strong>Total investments</strong></td>
<td>$869,550</td>
<td>$440,791</td>
<td>$29,739</td>
<td>$531,911</td>
<td>$1,871,991</td>
</tr>
<tr>
<td>Obligations under interest rate swap agreements</td>
<td>$ -</td>
<td>$ (14,782)</td>
<td>$ -</td>
<td>$ -</td>
<td>$ (14,782)</td>
</tr>
<tr>
<td>Other derivative liabilities</td>
<td>-</td>
<td>(867)</td>
<td>-</td>
<td>-</td>
<td>(867)</td>
</tr>
<tr>
<td><strong>Total liabilities at fair value</strong></td>
<td>$ -</td>
<td>$ (15,649)</td>
<td>$ -</td>
<td>$ -</td>
<td>$ (15,649)</td>
</tr>
</tbody>
</table>

There were no transfers between Level 1, 2, 3 or NAV during fiscal year 2019.
<table>
<thead>
<tr>
<th>Fair Value Measurements as of June 30, 2018</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
<th>Valued @ NAV</th>
<th>Total Fair Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marketable securities and short-term investment</td>
<td>$1,736</td>
<td>$28</td>
<td>-</td>
<td>$21,199</td>
<td>$22,963</td>
</tr>
<tr>
<td>Fixed Income Securities:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S. Government and Agency securities</td>
<td>-</td>
<td>226,069</td>
<td>-</td>
<td>-</td>
<td>226,069</td>
</tr>
<tr>
<td>Corporate Bonds</td>
<td>-</td>
<td>212,127</td>
<td>-</td>
<td>-</td>
<td>212,127</td>
</tr>
<tr>
<td>Asset Backed Securities and Other</td>
<td>-</td>
<td>47,605</td>
<td>-</td>
<td>-</td>
<td>47,605</td>
</tr>
<tr>
<td>Public Equity Securities</td>
<td>218,261</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>218,261</td>
</tr>
<tr>
<td>Fund Investments (Mutual/Commingled):</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fixed Income Funds</td>
<td>237,138</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>237,138</td>
</tr>
<tr>
<td>Public Equity Funds</td>
<td>214,974</td>
<td>-</td>
<td>-</td>
<td>261,265</td>
<td>476,239</td>
</tr>
<tr>
<td>Multi Asset Class Funds</td>
<td>160,367</td>
<td>-</td>
<td>-</td>
<td>27,266</td>
<td>187,633</td>
</tr>
<tr>
<td>Alternative Investments:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hedge Funds</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>82,609</td>
<td>82,609</td>
</tr>
<tr>
<td>Private Equity Partnerships</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>74,301</td>
<td>74,301</td>
</tr>
<tr>
<td>Private Debt</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>53,229</td>
<td>53,229</td>
</tr>
<tr>
<td>Other:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Derivative Assets</td>
<td>-</td>
<td>780</td>
<td>-</td>
<td>-</td>
<td>780</td>
</tr>
<tr>
<td>Trustee-held Investments</td>
<td>-</td>
<td>-</td>
<td>29,675</td>
<td>-</td>
<td>29,675</td>
</tr>
<tr>
<td>Pending Transactions</td>
<td>-</td>
<td>(45,113)</td>
<td>-</td>
<td>-</td>
<td>(45,113)</td>
</tr>
<tr>
<td>Total investments</td>
<td>$832,476</td>
<td>$441,496</td>
<td>$29,675</td>
<td>$519,869</td>
<td>$1,823,516</td>
</tr>
<tr>
<td>Obligations under interest rate swap agreements</td>
<td>$-</td>
<td>$(11,600)</td>
<td>-</td>
<td>$-</td>
<td>$(11,600)</td>
</tr>
<tr>
<td>Other derivative liabilities</td>
<td>-</td>
<td>(122)</td>
<td>-</td>
<td>-</td>
<td>(122)</td>
</tr>
<tr>
<td>Total liabilities at fair value</td>
<td>$-</td>
<td>$(11,722)</td>
<td>-</td>
<td>$-</td>
<td>$(11,722)</td>
</tr>
</tbody>
</table>

There were no transfers between Level 1, 2, 3 or NAV during fiscal year 2018.

Valuation Techniques and Inputs for Level 2 and Level 3 Instruments

The Level 2 and Level 3 instruments listed in the preceding fair value tables use the following valuation techniques and inputs as of the valuation date:

**Fixed Income Securities** — Fixed income securities consists primarily of U.S. Government and agency securities, corporate bonds, and asset backed securities, all of which are classified as Level 2. The fair value of investments in U.S. government and agency securities and corporate bonds was primarily determined using techniques consistent with the market approach, including matrix pricing and significant observable inputs of institutional bids, trade data, broker and dealer quotes, discount rates, issues spreads, and benchmark yield curves. The asset backed securities encompasses collateralized bond obligations, collateralized loan and mortgage obligations any other asset backed securities. The fair value of these securities was determined using techniques consistent with the market and income approach, such as discounted cash flows and matrix pricing.

**Beneficial Interest in Trusts** — The fair value of beneficial interests in perpetual and charitable trusts classified as Level 3 was determined using an income approach based on the present value of expected future cash flows to be received from the trust or based on Rush’s beneficial interest in the investments held in the trust measured at fair value. Since Rush is unable to liquidate the funds held and benefits only from the distributions generated off of such investments, the interest in such trusts are all shown in Level 3.
Obligations Under Interest Rate Swap Agreements — The fair value of Rush’s obligations under interest rate swap agreements classified as Level 2 is valued using a market approach. The valuation is based on a determination of market expectations relating to the future cash flows associated with the swap contract using sophisticated modeling based on observable market-based inputs, such as interest rate curves. The fair value of the obligation reported in Rush’s consolidated balance sheets includes an adjustment for the Obligated Group’s credit risk but may not be indicative of the value Rush would be required to pay upon early termination of the swap agreements.

The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while Rush believes that its methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

Level 3 Rollforward

A rollforward of the amounts in the consolidated balance sheets for financial instruments classified by Rush within Level 3 of the fair value hierarchy is as follows:

<table>
<thead>
<tr>
<th>Interest in Trusts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fair value — June 30, 2017</td>
</tr>
<tr>
<td>Actual return on investments — Realized and unrealized losses</td>
</tr>
<tr>
<td>Purchases</td>
</tr>
<tr>
<td>Sales</td>
</tr>
<tr>
<td>Fair value — June 30, 2018</td>
</tr>
<tr>
<td>Actual return on investments — Realized and unrealized gains</td>
</tr>
<tr>
<td>Purchases</td>
</tr>
<tr>
<td>Sales</td>
</tr>
<tr>
<td>Fair value — June 30, 2019</td>
</tr>
</tbody>
</table>

Investments in Entities that Report Fair Value Using NAV

Included within the fair value table above are investments in certain entities that report fair value using a calculated NAV or its equivalent. These investments consist of hedge fund of funds, private equity partnerships, and private debt within alternative investments. The NAV instruments listed in the fair value measurement tables use the following valuation techniques and inputs as of the valuation date:

Marketable Securities and Short Term Investments — Marketable securities and short term investments classified as NAV are invested in a short-term collective fund that serves as an investment vehicle for cash reserves. Fair value was determined using the calculated NAV as of the valuation date, based on a constant price. These funds are invested in high quality and short term money market instruments with daily liquidity.

Fund Investments — Investments within this category consist of public equity funds and multi-asset funds. The fair value of public equity funds classified at NAV are primarily determined using the calculated NAV at the valuation date under a market approach. This includes investments in commingled funds that invest primarily in domestic and foreign equity securities whose underlying values have a readily determinable market value or based on a net asset value. Multi-asset funds include investments in fund of funds that seek to provide both capital appreciation and income by investing in both traditional and alternative asset funds. The asset allocation is driven by the fund manager’s long-range
forecasts of asset-class real returns. Investments in this category classified as NAV are held in a commingled fund that invests primarily in global equity and bond mutual funds. Included in this category is a multistrategy hedge fund, priced on the last business day of each calendar month. The values for underlying investments are estimated based on many factors, including operating performance, balance sheet indicators, growth, and other market and business fundamentals. The underlying investment strategies can include long-short, global macro, fixed-income and currency hedges, and other tactical opportunity-related strategies.

**Alternative Investments** — Investments within this category consist primarily of hedge fund of funds, private equity partnerships, and private debt. The hedge fund of funds consist of diversified investments including equity long/short, credit long/short, event-drive, relative value, global opportunities, and other multistrategy funds. Hedge fund of funds investments are valued based on Rush’s ownership interest in the NAV of the respective fund as estimated by the general partner, which approximates fair value. Effective July 1, 2012, Rush elected to measure all new private equity partnerships entered into on or after July 1, 2012, at fair value (see Note 2). Private equity partnerships are valued based on the estimated fair values of the nonmarketable private equity partnerships in which it invests, which is an equivalent of NAV.

The following table summarizes the attributes relating to the nature and risk of such investments as of June 30, 2019:

<table>
<thead>
<tr>
<th>Entities that Report Fair Value Using NAV</th>
<th>Unfunded Redemption Commitments (In Thousands)</th>
<th>Redemption Frequency (If Currently Eligible)</th>
<th>Redemption Notice Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fund Investments (Mutual/Commingled)</td>
<td>None</td>
<td>Daily/Monthly</td>
<td>1-15 days</td>
</tr>
<tr>
<td>Alternative Investments:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hedge Funds</td>
<td>None</td>
<td>Quarterly</td>
<td>65-95 days</td>
</tr>
<tr>
<td>Private Equity Partnerships</td>
<td>$78,877</td>
<td>Not currently redeemable</td>
<td>N/A</td>
</tr>
<tr>
<td>Private Debt</td>
<td>$43,605</td>
<td>Not currently redeemable</td>
<td>N/A</td>
</tr>
<tr>
<td>Total</td>
<td>$122,482</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

7. **ENDOWMENT FUNDS**

Rush’s endowment consists of more than 400 individual funds, which are established for a variety of purposes. As required by GAAP, net assets associated with endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions.

**Interpretation of Relevant Law**

Rush has interpreted the Uniform Prudent Management of Institutional Funds Act (UPMIFA) as requiring preservation of the original value of the gift as of the gift date absent explicit donor stipulations to the contrary. As a result of this interpretation, Rush classifies as net assets with donor restrictions (a) the original value of gifts donated to the permanent endowment, (b) the original value of any subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable gift instrument at the time the accumulation is added to the fund. In accordance with UPMIFA, Rush considers the following factors in making a determination to appropriate or accumulate donor-restricted funds:

a. The duration and preservation of the fund
b. The purposes of the organization and the donor-restricted endowment fund
c. General economic conditions
d. The possible effect of inflation and deflation
e. The expected total return from income and the appreciation of investments
f. Other resources of the organization
g. The investment policies of the organization
Endowment Investment and Spending Policies

Rush has adopted endowment investment and spending policies to preserve purchasing power over the long term and provide stable annual support to the programs supported by the endowment, including professorships, research and education, free care, student financial aid, scholarships, and fellowships. Approximately 17% of Rush’s endowment is available for general purposes for the years ended June 30, 2019 and 2018.

The Investment Committee of the Board of Trustees is responsible for defining and reviewing the investment policy to determine an appropriate long-term asset allocation policy. The asset allocation policy reflects the objective with allocations structured for capital growth and inflation protection over the long term. The current asset allocation targets and ranges as well as the asset allocation as of June 30, 2019 and 2018, are as follows:

<table>
<thead>
<tr>
<th>Asset Class</th>
<th>Target Allocation and Range</th>
<th>Percentage of Endowment Assets</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2019</td>
<td>2018</td>
</tr>
<tr>
<td>Global equity</td>
<td>55% (+/− 5%)</td>
<td>56 %</td>
</tr>
<tr>
<td>Multi Asset Fund</td>
<td>10% (+/− 5%)</td>
<td>12</td>
</tr>
<tr>
<td>Private equity</td>
<td>15% (+/− 5%)</td>
<td>18</td>
</tr>
<tr>
<td>Fixed income</td>
<td>20% (+/− 5%)</td>
<td>14</td>
</tr>
</tbody>
</table>

To achieve its long-term rate of return objectives, Rush relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current income (interest and dividends). The expected long-term rate of return target of the endowment given its current asset allocation structure is approximately 7.0%. Actual returns in any given year may vary from this amount. Rush has established market-related benchmarks to evaluate the endowment fund’s performance on an ongoing basis.

The Finance Committee of the Board of Trustees approves the annual spending policy for program support. In establishing the annual spending policy, Rush’s main objectives are to provide for intergenerational equity over the long term, the concept that future beneficiaries will receive the same level of support as current beneficiaries on an inflation-adjusted basis, and to maximize annual support to the programs supported by the endowment. The spending rate was 4.0% for the fiscal years ended June 30, 2019 and 2018 and income from the endowment fund provided $20,126 and $19,190 of support for Rush’s programs during the fiscal years ended June 30, 2019 and 2018, respectively.

Composition of Endowment Fund and Reconciliation

The endowment net asset composition by type of fund as of June 30, 2019, consisted of the following:

<table>
<thead>
<tr>
<th>Without Restrictions</th>
<th>With Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donor-restricted endowment funds</td>
<td>$ -</td>
<td>$ 640,339</td>
</tr>
<tr>
<td>Board-designated endowment funds</td>
<td>13,026</td>
<td>-</td>
</tr>
<tr>
<td>Total funds</td>
<td>$ 13,026</td>
<td>$ 640,339</td>
</tr>
</tbody>
</table>
Changes in endowment net assets for the fiscal year ended June 30, 2019, consisted of the following:

<table>
<thead>
<tr>
<th></th>
<th>Without Restrictions</th>
<th>With Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endowment net assets — June 30, 2018</td>
<td>$7,988</td>
<td>$630,156</td>
<td>$638,144</td>
</tr>
<tr>
<td>Contributions</td>
<td>5,000</td>
<td>3,567</td>
<td>8,567</td>
</tr>
<tr>
<td>Net investment return</td>
<td>211</td>
<td>26,729</td>
<td>26,940</td>
</tr>
<tr>
<td>Transfer of endowment appreciation</td>
<td>(173)</td>
<td>(20,113)</td>
<td>(20,286)</td>
</tr>
<tr>
<td>Endowment net assets — June 30, 2019</td>
<td>$13,026</td>
<td>$640,339</td>
<td>$653,365</td>
</tr>
</tbody>
</table>

The endowment net asset composition by type of fund as of June 30, 2018, consisted of the following:

<table>
<thead>
<tr>
<th></th>
<th>Without Restrictions</th>
<th>With Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donor-restricted endowment funds</td>
<td>-</td>
<td>$630,156</td>
<td>$630,156</td>
</tr>
<tr>
<td>Board-designated endowment funds</td>
<td>7,988</td>
<td>-</td>
<td>7,988</td>
</tr>
<tr>
<td>Total funds</td>
<td>$7,988</td>
<td>$630,156</td>
<td>$638,144</td>
</tr>
</tbody>
</table>

Changes in endowment net assets for the fiscal year ended June 30, 2018, consisted of the following:

<table>
<thead>
<tr>
<th></th>
<th>Without Restrictions</th>
<th>With Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endowment net assets — June 30, 2017</td>
<td>$7,752</td>
<td>$590,675</td>
<td>$598,427</td>
</tr>
<tr>
<td>Contributions</td>
<td>-</td>
<td>7,782</td>
<td>7,782</td>
</tr>
<tr>
<td>Net investment return</td>
<td>420</td>
<td>51,017</td>
<td>51,437</td>
</tr>
<tr>
<td>Transfer of endowment appreciation</td>
<td>(184)</td>
<td>(19,318)</td>
<td>(19,502)</td>
</tr>
<tr>
<td>Endowment net assets — June 30, 2018</td>
<td>$7,988</td>
<td>$630,156</td>
<td>$638,144</td>
</tr>
</tbody>
</table>

**Fund Deficiencies**

Rush monitors the accumulated losses on investments within net assets restricted by donors to be maintained in perpetuity to determine whether the endowment corpus has been impaired. The endowment funds are invested in an investment pool, which also includes investments with net assets restricted by donors for a specific time period or purpose and investments within net assets without donor restrictions. No endowments were impaired for fiscal years ending June 30, 2019 and 2018.
8. **PROPERTY AND EQUIPMENT**

Property and equipment as of June 30, 2019 and 2018 consisted of the following:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Land and buildings</td>
<td>$2,110,350</td>
<td>$2,082,657</td>
</tr>
<tr>
<td>Equipment</td>
<td>$822,928</td>
<td>$763,476</td>
</tr>
<tr>
<td>Construction in progress</td>
<td>$221,838</td>
<td>$163,003</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$3,155,116</td>
<td>$3,009,136</td>
</tr>
<tr>
<td>Less accumulated depreciation</td>
<td>(1,602,175)</td>
<td>(1,511,504)</td>
</tr>
<tr>
<td><strong>Property and equipment, net</strong></td>
<td>$1,552,941</td>
<td>$1,497,632</td>
</tr>
</tbody>
</table>

Property and equipment, net, includes $1,656 and $39,581 in leased property and equipment as of June 30, 2019 and 2018, respectively. Accumulated depreciation on leased property and equipment amounted to $452 and $22,977 as of June 30, 2019 and 2018, respectively.

Rush continues to make campus improvements and has a number of construction projects planned with a Master Facility Plan that began in fiscal year 2017. As of June 30, 2019 and 2018, Rush had construction commitments outstanding of $145,425 and $70,937, respectively.

9. **LONG-TERM DEBT AND CREDIT ARRANGEMENTS**

Rush’s long-term debt is issued under a Master Trust Indenture, which established the Obligated Group composed of RUMC and RCMC. The Obligated Group is jointly and severally liable for the obligations issued under the Master Trust Indenture. Each Obligated Group member is expected to pay its allocated share of the debt issued on its behalf. As of June 30, 2019 and 2018, such issuances are secured by a pledge of gross receipts, as defined, of the Obligated Group members.
A summary of Rush’s long-term debt as of June 30, 2019 and 2018, is as follows:

<table>
<thead>
<tr>
<th>Illinois Finance Authority Revenue Bonds:</th>
<th>Interest Rates</th>
<th>Final Maturity Date</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixed-rate revenue bonds:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Series 2015 A/B</td>
<td>5.00%</td>
<td>November 15, 2039</td>
<td>$457,475</td>
<td>$466,365</td>
</tr>
<tr>
<td>Variable-rate revenue bonds:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Series 2016</td>
<td>Average of 2.89% and 1.78% in FY2019 and FY2018, respectively</td>
<td>November 1, 2045</td>
<td>50,000</td>
<td>50,000</td>
</tr>
<tr>
<td>Series 2011, Tax-Exempt Private Placement with a commercial bank</td>
<td>Average of 2.73% and 1.67% in FY2019 and FY2018, respectively</td>
<td>November 1, 2024</td>
<td>31,405</td>
<td>34,665</td>
</tr>
<tr>
<td>Total variable rate debt</td>
<td></td>
<td></td>
<td>81,405</td>
<td>84,665</td>
</tr>
<tr>
<td>Total tax-exempt debt</td>
<td></td>
<td></td>
<td>538,880</td>
<td>551,030</td>
</tr>
</tbody>
</table>

Other Debt:
- Mortgage loan, collateralized by fitness center 4.40% May 2021 2,006 2,986
- Line of Credit 3.20% August 29, 2019 36,500 36,500

Total par value of debt 577,386 590,516
Less current portion of long-term debt (14,270) (13,156)
Deferred Financing Costs (3,827) (4,606)
Less unamortized premium 57,463 62,117

Long-term debt $616,752 $634,871

Under its various indebtedness agreements, the Obligated Group is subject to certain financial covenants, including maintaining a minimum historical debt service coverage and maximum annual debt service coverage ratios; maintaining minimum levels of days cash on hand; limitations on selling, leasing, or otherwise disposing of Obligated Group property; and certain other nonfinancial covenants. Management believes the Obligated Group was in compliance with its financial covenants as of June 30, 2019 and 2018.

Annual maturities of outstanding long-term debt are as follows:

<table>
<thead>
<tr>
<th>Years Ending June 30</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>$14,270</td>
</tr>
<tr>
<td>2021</td>
<td>15,121</td>
</tr>
<tr>
<td>2022</td>
<td>15,740</td>
</tr>
<tr>
<td>2023</td>
<td>16,600</td>
</tr>
<tr>
<td>2024</td>
<td>17,975</td>
</tr>
<tr>
<td>Thereafter</td>
<td>497,680</td>
</tr>
<tr>
<td>Total</td>
<td>$577,386</td>
</tr>
</tbody>
</table>

Lines of Credit Arrangements

The Obligated Group had a $100 million short-term line of credit with a bank as of June 30, 2018, which would mature on December 31, 2020. In fiscal year 2019, this short-term line of credit was refinanced and reduced to $75 million with a December 31, 2021 maturity date. Any borrowings on this short-term line of credit are due and payable in 180 days. As of June 30, 2019 and 2018, the Obligated Group had $36,500 outstanding on this line of credit.
On August 29, 2019, the Obligated Group issued Series 2019 fixed-rate tax exempt revenue bonds for $36,752, the proceeds of which were used to pay off the outstanding line of credit borrowings of $36,500 and reimburse RCMC for certain costs. The bonds mature on September 1, 2049.

10. DERIVATIVES

Derivatives Policy

The Obligated Group uses derivative instruments, specifically interest rate swaps, to manage its exposure to changes in interest rates on variable rate borrowings. The use of derivative instruments exposes the Obligated Group to additional risks related to the derivative instrument, including market, credit, and termination, as described below, and the Obligated Group has defined risk management practices to mitigate these risks.

Market risk represents the potential adverse effect on the fair value and cash flow of a derivative instrument due to changes in interest rates or rate spreads. Market risk is managed through ongoing monitoring of interest rate exposure based on set parameters regarding the type and degree of market risk that the Obligated Group will accept. Credit risk is the risk that the counterparty on a derivative instrument may be unable to perform its obligations during the term of the contract. When the fair value of a derivative contract is positive (an asset to the Obligated Group), the counterparty owes the Obligated Group, which creates credit risk. Credit risk is managed by setting stringent requirements for qualified counterparties at the date of execution of a derivative transaction and requiring counterparties to post collateral in the event of a credit rating downgrade or if the fair value of the derivative contract exceeds a negotiated threshold. Termination risk represents the risk that the Obligated Group may be required to make a significant payment to the counterparty if the derivative contract is terminated early. Termination risk is assessed at onset by performing a statistical analysis of the potential for a significant termination payment under various scenarios designed to encompass expected interest rate changes over the life of the proposed contract. The test measures the ability to make a termination payment without a significant impairment to the Obligated Group’s ability to meet its debt or liquidity covenants.

Board approval is required to enter or modify any derivatives transaction. Management periodically reviews existing derivative positions as its risk tolerance and cost of capital changes over time.

Interest Rate Swap Agreements

The Obligated Group has two interest rate swap agreements (the “Swap Agreements”), which were designed to synthetically fix the interest payments on its Series 2006A Bonds. Under the Swap Agreements, the Obligated Group makes fixed-rate payments equal to 3.945% to the swap counterparties and receives variable-rate payments equal to 68% of London InterBank Offered Rate (1.613% and 1.421% as of June 30, 2019 and 2018, respectively) from the swap counterparties, each calculated on the notional amount of the Swap Agreements. As of June 30, 2019 and 2018, the Swap Agreements had a notional amount of $75,400 and $79,150, respectively ($37,700 in notional amount with each counterparty). Following the refinancing of the Series 2006A Bonds, the Obligated Group used $50,000 in notional amount of the Swap Agreements to synthetically fix the interest on the Series 2008A Bonds, which were refinanced into the Series 2016 Bonds. The Swap Agreements each expire on November 1, 2035, and amortize annually commencing in November 2012. The Swap Agreements are secured by obligations issued under the Master Trust Indenture.

The Swap Agreements also require either party to post collateral in the form of cash and certain cash equivalents to secure potential termination payments. The amount of collateral that is required to be posted is based on the relevant party’s long-term credit rating. Based on its current rating, the Obligated Group is required to post collateral with the Swap Counterparties in the event that the market value of the Swap Agreements exceeds $(25,000) or $(12,500) for each Swap Agreement. As of June 30, 2019 and 2018, the Obligated Group had no collateral posted under Swap Agreements.
The fair value of the Swap Agreements was as follows as of June 30, 2019 and 2018:

<table>
<thead>
<tr>
<th>Reported As</th>
<th>June 30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obligations under Swap Agreements</td>
<td>$ (14,782)</td>
</tr>
<tr>
<td>Collateral posted under Swap Agreements</td>
<td></td>
</tr>
<tr>
<td>Other long-term liabilities</td>
<td></td>
</tr>
<tr>
<td>Other current assets</td>
<td></td>
</tr>
<tr>
<td>Obligations under Swap Agreements, net</td>
<td>$ (14,782)</td>
</tr>
</tbody>
</table>

The fair value of the Swap Agreements reported in Rush’s consolidated balance sheets as of June 30, 2019 and 2018, includes an adjustment for the Obligated Group’s credit risk and may not be indicative of the termination value that Rush would be required to pay upon early termination of the Swap Agreements.

Management has not designated the Swap Agreements as hedging instruments. Amounts recorded in the accompanying consolidated statements of operations and changes in net assets for the Swap Agreements allocated to Rush for the fiscal years ended June 30, 2019 and 2018, were as follows:

<table>
<thead>
<tr>
<th>Reported As</th>
<th>Fiscal Years Ended</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in fair value of interest rate swaps</td>
<td>$ (3,182)</td>
</tr>
<tr>
<td>Nonoperating (expense) income</td>
<td>$ 4,402</td>
</tr>
<tr>
<td>Net cash payments on interest rate swaps</td>
<td>$ (1,796)</td>
</tr>
<tr>
<td>Interest expense</td>
<td>$ (2,323)</td>
</tr>
</tbody>
</table>

11. OBLIGATIONS UNDER CAPITAL LEASE AND OTHER FINANCING ARRANGEMENTS

RUMC is party to certain capital lease and long-term financing arrangements relating to medical and office equipment and buildings. Expiration of leases ranges from 2016 to 2024. Annual interest expense under these lease agreements was $2,112 and $1,930 for the years ended June 30, 2019 and 2018, respectively. Assets acquired under capital lease arrangements are included in property and equipment, net, in the accompanying consolidated balance sheets. During fiscal years 2019 and 2018, one of Rush’s joint ventures, Rush Oak Brook Orthopaedic, LLC, had draws of $6,285 and $34,715, respectively, from a construction line of credit to finance the construction of a new medical office building in Oak Brook, Illinois. The outstanding balance is recorded within other financing arrangements of the accompanying consolidated balance sheet, which totaled $40,790 as of June 30, 2019. RUMC guarantees 25% of the outstanding balance until certain metrics within the credit agreement are achieved.
Future minimum lease payments under noncancelable capital leases and other financing arrangements are as follows:

<table>
<thead>
<tr>
<th>Years Ending</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>June 30</td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td>$5,480</td>
</tr>
<tr>
<td>2021</td>
<td>3,170</td>
</tr>
<tr>
<td>2022</td>
<td>3,216</td>
</tr>
<tr>
<td>2023</td>
<td>3,290</td>
</tr>
<tr>
<td>2024</td>
<td>3,321</td>
</tr>
<tr>
<td>Thereafter</td>
<td>37,850</td>
</tr>
</tbody>
</table>

Total minimum payments: $56,327
Less amount representing interest: $(12,616)
Net present value of obligations under capital lease and other financing arrangements: $43,711
Less current portions included in accounts payable: $(1,941)
Long-term portion of obligations under capital lease and other financing arrangements: $41,770

12. PENSION AND OTHER POSTRETIREMENT BENEFIT PLANS

RUMC maintains a defined benefit pension plan, defined contribution plans, and other postretirement benefit plans that together cover substantially all of RUMC’s employees.

Prior to January 1, 2012, RUMC had two defined benefit pension plans, the Retirement Plan and the Pension Plan (collectively, the “Defined Benefit Pension Plans”), covering substantially all of its employees. Benefits are based on the years of service and the employee’s final average earnings, as defined. Plan assets and obligations are measured as of June 30 (the “Measurement Date”) each year.

Effective as of the close of business on December 31, 2011, the Pension Plan, representing certain union employees, was amended to freeze benefit accruals for all participants. No additional benefits will accrue, and no additional individuals will become plan participants in the Pension Plan as of January 1, 2012. Also, effective December 31, 2011, the Pension Plan was merged into the Retirement Plan with all accrued benefits of the Pension Plan participants preserved as part of the merger. Effective January 1, 2012, the Retirement Plan was amended to include eligible union members previously covered by the Pension Plan.

Effective January 1, 2015 (the “effective date”), a new defined benefit plan was established. This new plan (the “Pre-2015 Separations Plan” or the “Pre-2015 Plan”), is a spinoff of the current Retirement Plan. The Retirement Plan’s benefit obligation and assets attributable to participants who terminated employment prior to January 1, 2015, with a vested benefit were transferred to the Pre-2015 Plan as of the effective date. On the effective date, $648,066 of benefit obligations and $625,334 of assets were transferred from the Retirement Plan into the Pre-2015 Plan.

Rush offered an enhanced retirement opportunity (“ERO”) to certain RUMC and ROPH employees meeting eligibility requirements during fiscal year 2019, resulting in a total settlement of $69,416. In addition, the ERO triggered a one-time non-cash charge of $23,235 as a result of the total payments exceeding the plan’s interest cost and service cost components in fiscal year 2019, which is recorded as pension settlement expense within the accompanying consolidated statement of operations and changes in net assets.
In addition to the pension programs, RUMC also provides postretirement health care benefits for certain employees (the “Postretirement Healthcare Plans”). Further benefits under the Postretirement Healthcare Plans have been curtailed.

**Obligations and Funded Status**

The table below sets forth the accumulated benefit obligation, the change in the projected benefit obligation, and the change in the plan assets of the Defined Benefit Pension Plans and Postretirement Healthcare Plans (collectively, the “Plans”). The table also reflects the funded status of the Plans as of the Measurement Date and amounts recognized in RUMC’s component balance sheets as of June 30, 2019 and 2018.

<table>
<thead>
<tr>
<th>Obligations and Funded Status</th>
<th>Defined Benefit Pension Plans</th>
<th>Postretirement Healthcare Plans</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actuarial present value of benefit obligations — accumulated benefit obligation</td>
<td>$ 1,050,875</td>
<td>$ 1,008,810</td>
</tr>
<tr>
<td>Change in projected benefit obligations:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Projected benefit obligation — beginning of measurement period</td>
<td>$ 1,032,807</td>
<td>$ 1,065,233</td>
</tr>
<tr>
<td>Service costs</td>
<td>21,741</td>
<td>21,743</td>
</tr>
<tr>
<td>Interest costs</td>
<td>45,040</td>
<td>43,325</td>
</tr>
<tr>
<td>Employee contributions</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Special termination benefits</td>
<td>10,298</td>
<td>-</td>
</tr>
<tr>
<td>Plan settlements</td>
<td>(69,416)</td>
<td>(406)</td>
</tr>
<tr>
<td>Actuarial (gain) loss</td>
<td>83,496</td>
<td>(47,893)</td>
</tr>
<tr>
<td>Benefits paid</td>
<td>(44,473)</td>
<td>(49,195)</td>
</tr>
<tr>
<td>Projected benefit obligation - end of measurement period</td>
<td>$ 1,079,493</td>
<td>$ 1,032,807</td>
</tr>
<tr>
<td>Change in plan assets:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fair value of plan assets — beginning of measurement period</td>
<td>$ 1,014,502</td>
<td>$ 1,003,729</td>
</tr>
<tr>
<td>Actual return on plan assets</td>
<td>101,700</td>
<td>25,968</td>
</tr>
<tr>
<td>Employer contributions</td>
<td>35,341</td>
<td>34,406</td>
</tr>
<tr>
<td>Plan participant contributions</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Plan settlements</td>
<td>(69,416)</td>
<td>(406)</td>
</tr>
<tr>
<td>Benefits paid</td>
<td>(44,473)</td>
<td>(49,195)</td>
</tr>
<tr>
<td>Fair value of plan assets — end of measurement period</td>
<td>$ 1,037,654</td>
<td>$ 1,014,502</td>
</tr>
<tr>
<td>Accrued benefit liability</td>
<td>$ 41,839</td>
<td>$ 18,305</td>
</tr>
</tbody>
</table>

The actuarial cost method used to compute the Defined Benefit Pension Plans liabilities and expenses is the projected unit credit method.
The components of net periodic pension cost for the Plans were as follows:

### The table below sets forth the change in the accrued benefit liability of the Plans

<table>
<thead>
<tr>
<th>Accrued Benefit Liability</th>
<th>Defined Benefit Pension Plans</th>
<th>Postretirement Healthcare Plans</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accrued benefit liability — beginning of measurement period</td>
<td>$18,305</td>
<td>$61,505</td>
</tr>
<tr>
<td>Fiscal year activity:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net periodic pension cost</td>
<td>23,683</td>
<td>8,080</td>
</tr>
<tr>
<td>Employer contributions</td>
<td>35,341</td>
<td>(34,406)</td>
</tr>
<tr>
<td>Post retirement-related changes and other net periodic postretirement costs:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Actuarial (gain) loss</td>
<td>43,915</td>
<td>(7,376)</td>
</tr>
<tr>
<td>Reclassification adjustment for losses reflected in periodic expense</td>
<td>(8,723)</td>
<td>(9,498)</td>
</tr>
<tr>
<td>Accrued benefit liability — end of measurement period</td>
<td>$41,839</td>
<td>$18,305</td>
</tr>
<tr>
<td>Recognized in the consolidated balance sheets as follows:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accrued expenses</td>
<td>$ -</td>
<td>$ -</td>
</tr>
<tr>
<td>Noncurrent liabilities</td>
<td>$41,839</td>
<td>$18,305</td>
</tr>
<tr>
<td></td>
<td>$41,839</td>
<td>$18,305</td>
</tr>
</tbody>
</table>

In accordance with FASB guidance regarding accounting for defined benefit pension and other postretirement plans, all previously unrecognized actuarial losses and prior service costs are reflected in the consolidated balance sheets. The postretirement-related charges other than net periodic benefit cost related to the Defined Benefit Pension Plans and Postretirement Healthcare Plans are included as a separate (decrease) increase to net assets without restrictions and total $(22,270) and $18,210 for fiscal years 2019 and 2018, respectively. For fiscal year 2019, this amount includes actuarial gains arising during fiscal year 2018 of $(43,448) and a reclassification adjustment for losses reflected in periodic expense in fiscal year 2019 of $8,356. For fiscal year 2018, this amount includes actuarial gains arising during fiscal year 2017 of $8,708 and a reclassification adjustment for losses reflected in periodic expense in fiscal year 2018 of $9,502.
The Defined Benefit Pension Plans and Postretirement Healthcare Plans items not yet recognized as a component of periodic pension and postretirement medical plan expense, but included within net assets without restrictions as of and for the years ended June 30, 2019 and 2018, are as follows:

<table>
<thead>
<tr>
<th></th>
<th>Defined Benefit Pension Plans</th>
<th>Postretirement Healthcare Plans</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2019</td>
<td>2018</td>
</tr>
<tr>
<td>Unrecognized prior service credit</td>
<td>$1,930 $2,595</td>
<td>$ - $ -</td>
</tr>
<tr>
<td>Unrecognized net actuarial (loss) gain</td>
<td>(277,683) (255,979)</td>
<td>1,304 1,205</td>
</tr>
<tr>
<td>Total</td>
<td>$(275,753) $(253,384)</td>
<td>$1,304 $1,205</td>
</tr>
</tbody>
</table>

An estimated $665 in prior service credit and ($10,783) in net actuarial loss will be included as components of periodic pension expense in fiscal year 2020. An estimated $548 in net actuarial gain will be included as components of periodic postretirement expense in fiscal year 2020.

**Assumptions**

The actuarial assumptions used to determine benefit obligations at the measurement date and net periodic benefit cost for the Plans are as follows:

<table>
<thead>
<tr>
<th>Assumptions Used to Determine Benefit Obligations and Net Periodic Benefit Cost</th>
<th>Defined Benefit Pension Plans</th>
<th>Postretirement Healthcare Plans</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-2015</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Retirement Plan</td>
<td>Separations Plan</td>
</tr>
<tr>
<td>Discount rate — benefit obligation</td>
<td>3.75 % 4.45 %</td>
<td>3.65 % 4.45 %</td>
</tr>
<tr>
<td>Discount rate — pension expense</td>
<td>4.45 4.15</td>
<td>4.45 4.05</td>
</tr>
<tr>
<td>Rate of increase in compensation levels</td>
<td>5.42 5.42</td>
<td>- -</td>
</tr>
<tr>
<td>Expected long-term rate of return on plan assets</td>
<td>6.90 7.00</td>
<td>5.75 6.50</td>
</tr>
<tr>
<td>Health care cost trend rate (initial)</td>
<td>- -</td>
<td>- -</td>
</tr>
<tr>
<td>Health care cost trend rate (ultimate)</td>
<td>- -</td>
<td>- -</td>
</tr>
<tr>
<td>Year the rate reaches ultimate trend rate</td>
<td>- -</td>
<td>- -</td>
</tr>
</tbody>
</table>

The discount rate used is based on a spot interest rate yield curve based on a broad group of corporate bonds rated AA or better as of the Measurement Date. Rush uses this yield curve and the estimated payouts of the Plans to develop an aggregate discount rate. The estimated payouts are the sum of the payouts under the Defined Benefit Pension Plan(s) and the Postretirement Healthcare Plans. For fiscal years 2019 and 2018, the discount rate was estimated under a bond model approach, which is based on a hypothetical bond portfolio whose cash flow from coupons and maturities match the year-by-year Plans’ cash flows using bonds rated AA or better.

For the years ended June 30, 2019 and 2018, the actual rate of return on plan assets was 11.4% and 3.1%, respectively.

**Plan Assets**

RUMC’s investment objective for its Defined Benefit Pension Plans is to achieve a total return on plan assets that meets or exceeds the return on the plan’s liability over a full market cycle with consideration of the plan’s current funded status. Investment risk is effectively managed through diversification of assets for a mix of capital growth and capital
protection across various investment styles. The asset allocation policy reflects this objective with allocations to return generating assets (e.g., equity and alternative investments, consisting of hedge funds and limited partnerships) and interest rate hedging assets (e.g., fixed-income securities).

All of the plan’s assets are measured at fair value, including alternative investments. Fair value methodologies used to assign plan assets to levels of FASB’s valuation hierarchy are consistent with the inputs described in Note 6. Fair value methodologies used to value interests in private equity limited partnerships that hold restricted securities and are not publicly traded are based on RUMC’s ownership interest in the NAV of the respective fund as estimated by the general partner, which approximates fair value. RUMC routinely monitors and assesses methodologies and assumptions used in valuing these interests.

The fair value of the Defined Benefit Pension Plan assets as of June 30, 2019 and 2018 is as follows:

<table>
<thead>
<tr>
<th>Fair Value Measurements as of June 30, 2019</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
<th>Valued @ NAV</th>
<th>Total Fair Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marketable securities and short-term investments</td>
<td>$ - $</td>
<td>$ - $</td>
<td>$ - $</td>
<td>$ 18,290</td>
<td>$ 18,290</td>
</tr>
<tr>
<td>Fixed Income Securities:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S. Government and Agency securities</td>
<td>-</td>
<td>428,073</td>
<td>-</td>
<td>-</td>
<td>428,073</td>
</tr>
<tr>
<td>Corporate Bonds</td>
<td>84,005</td>
<td>403,549</td>
<td>-</td>
<td>-</td>
<td>487,554</td>
</tr>
<tr>
<td>Asset Backed Securities and Other</td>
<td>-</td>
<td>35,940</td>
<td>-</td>
<td>-</td>
<td>35,940</td>
</tr>
<tr>
<td>Public Equity Securities</td>
<td>65,733</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>65,733</td>
</tr>
<tr>
<td>Fixed Income Securities:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corporate Bonds</td>
<td>84,005</td>
<td>403,549</td>
<td>-</td>
<td>-</td>
<td>487,554</td>
</tr>
<tr>
<td>Asset Backed Securities and Other</td>
<td>-</td>
<td>35,940</td>
<td>-</td>
<td>-</td>
<td>35,940</td>
</tr>
<tr>
<td>Public Equity Securities</td>
<td>65,733</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>65,733</td>
</tr>
<tr>
<td>Fund Investments (Mutual/Commingled):</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Public Equity Funds</td>
<td>9,890</td>
<td>-</td>
<td>-</td>
<td>115,647</td>
<td>125,537</td>
</tr>
<tr>
<td>Multi Asset Class Funds</td>
<td>46,230</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>46,230</td>
</tr>
<tr>
<td>Alternative Investments:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Private Equity Partnerships</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>18,420</td>
<td>18,420</td>
</tr>
<tr>
<td>Other:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Derivative Assets</td>
<td>-</td>
<td>6,573</td>
<td>-</td>
<td>-</td>
<td>6,573</td>
</tr>
<tr>
<td>Pending Transactions</td>
<td>-</td>
<td>(191,523)</td>
<td>-</td>
<td>-</td>
<td>(191,523)</td>
</tr>
<tr>
<td>Total Plan Assets</td>
<td>$ 205,858</td>
<td>$ 682,612</td>
<td>$ -</td>
<td>$ 152,357</td>
<td>$ 1,040,827</td>
</tr>
<tr>
<td>Liabilities</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Derivative Liabilities</td>
<td>-</td>
<td>(9,267)</td>
<td>-</td>
<td>(1,490)</td>
<td>(10,757)</td>
</tr>
<tr>
<td>Total Liabilities at Fair Value</td>
<td>$ -</td>
<td>$ (9,267)</td>
<td>$ -</td>
<td>$ (1,490)</td>
<td>$ (10,757)</td>
</tr>
</tbody>
</table>

There were no transfers between Level 1, 2, 3 or NAV during fiscal year 2019.
The table below provides a breakdown of the fair value measurements as of June 30, 2018:

<table>
<thead>
<tr>
<th>Fair Value Measurements as of June 30, 2018</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
<th>Valued @ NAV</th>
<th>Fair Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marketable securities and short-term investments</td>
<td>$ -</td>
<td>$ -</td>
<td>$ -</td>
<td>$ 10,548</td>
<td>$ 10,548</td>
</tr>
<tr>
<td>Fixed Income Securities:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S. Government and Agency securities</td>
<td>-</td>
<td>301,548</td>
<td>-</td>
<td>-</td>
<td>301,548</td>
</tr>
<tr>
<td>Corporate Bonds</td>
<td>86,443</td>
<td>344,417</td>
<td>-</td>
<td>-</td>
<td>430,860</td>
</tr>
<tr>
<td>Asset Backed Securities and Other</td>
<td>-</td>
<td>35,793</td>
<td>-</td>
<td>-</td>
<td>35,793</td>
</tr>
<tr>
<td>Public Equity Securities</td>
<td>86,036</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>86,036</td>
</tr>
<tr>
<td>Fund Investments (Mutual/Commingled):</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Public Equity Funds</td>
<td>9,931</td>
<td>-</td>
<td>-</td>
<td>144,304</td>
<td>154,235</td>
</tr>
<tr>
<td>Multi Asset Class Funds</td>
<td>75,814</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>75,814</td>
</tr>
<tr>
<td>Alternative Investments:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Private Equity Partnerships</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>20,263</td>
<td>20,263</td>
</tr>
<tr>
<td>Other:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Derivative Assets</td>
<td>-</td>
<td>8,967</td>
<td>-</td>
<td>-</td>
<td>8,967</td>
</tr>
<tr>
<td>Pending Transactions</td>
<td>-</td>
<td>(109,618)</td>
<td>-</td>
<td>-</td>
<td>(109,618)</td>
</tr>
<tr>
<td>Total Plan Assets</td>
<td>$ 258,225</td>
<td>$ 581,108</td>
<td>$ -</td>
<td>$ 175,115</td>
<td>$ 1,014,447</td>
</tr>
</tbody>
</table>

| Liabilities | | | | | |
| Derivative Liabilities | - | (6,487) | - | - | (6,487) |
| Total Liabilities at Fair Value | $ - | $ (6,487) | $ - | $ - | $ (6,487) |

There were no transfers between Level 1, 2, 3 or NAV during fiscal year 2018.

As of June 30, 2019 and 2018, the defined benefit pension plan’s commitments for additional contributions to alternative investments totaled $3,130 and $3,169, respectively.

**Cash Flows**

RUMC expects to make estimated contributions to and benefit payments from its Defined Benefit Pension Plans and Postretirement Healthcare Plans for the years ending June 30 as follows:

<table>
<thead>
<tr>
<th>Expected contributions in 2020</th>
<th>Defined Benefit Pension Plans</th>
<th>Postretirement Healthcare Plans</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ 34,562</td>
<td>$ 465</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Estimated Benefit Payments</th>
<th>Defined Benefit Pension Plans</th>
<th>Postretirement Healthcare Plans</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>$ 65,033</td>
<td>$ 465</td>
</tr>
<tr>
<td>2021</td>
<td>63,863</td>
<td>451</td>
</tr>
<tr>
<td>2022</td>
<td>67,405</td>
<td>464</td>
</tr>
<tr>
<td>2023</td>
<td>67,284</td>
<td>483</td>
</tr>
<tr>
<td>2024</td>
<td>69,265</td>
<td>533</td>
</tr>
<tr>
<td>2025 through 2029</td>
<td>347,160</td>
<td>2,803</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$ 680,010</td>
<td>$ 5,199</td>
</tr>
</tbody>
</table>
Other Postretirement Benefit Plans

Both RUMC and RCMC maintain a voluntary tax-deferred retirement savings plan. Under these defined contribution plans, employees may elect to contribute a percentage of their salary, which may be matched in accordance with the provisions of the plans. Other provisions of the plans may provide for employer contributions to the plans based on eligible earnings, regardless of whether the employee elects to contribute to the plan. Maximum annual contributions are limited by federal regulations. Employer contributions to these Plans were $24,468 and $19,901 for the years ended June 30, 2019 and 2018, respectively.

RUMC also sponsors a noncontributory defined contribution plan covering selected employees (“457(b) Plan”). Contributions to the 457(b) Plan are based on a percentage of qualifying compensation up to certain limits as defined by the provisions of the 457(b) Plan. The 457(b) Plan assets and liabilities totaled $24,468 and $26,483 as of June 30, 2019 and 2018, respectively, and are included in investments — less current portion and other long-term liabilities in the accompanying consolidated balance sheets. The assets of the 457(b) Plan are subject to the claims of the general creditors of RUMC.

Both RUMC and RCMC also sponsor supplemental retirement plans for certain management employees (the “Plans”). The RUMC plans include a Supplement plan, which was frozen as of December 31, 2014, and replaced with the Executive Retirement Plan. The Plans are noncontributory and annual benefits are credited to each participant’s account based on a percentage of qualifying compensation, as defined by the provisions of the plan. Assets set aside to fund the Supplemental Plans amounted to $12,427 and $10,812 as of June 30, 2019 and 2018, respectively, and are included in investments — less current portion in the accompanying consolidated balance sheets. These supplemental retirement plans are currently funded at 92% of benefits accrued.

RUMC also maintains a frozen nonqualified supplemental defined benefit retirement plan for certain management employees, which is unfunded. Benefits under the supplemental defined benefit plan, which were curtailed as of December 31, 2004, are paid when incurred from operating funds.

It is RUMC’s policy to meet the requirement of the Employee Retirement Income Security Act of 1974 and the Pension Protection Act of 2006.

13. CONCENTRATION OF CREDIT RISK

Rush grants credit without collateral to its patients, most of whom are local residents and are insured under third-party payor agreements. The mix of patient accounts receivable from patients and third-party payors as of June 30, 2019 and 2018 was as follows:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicare</td>
<td>19 %</td>
<td>17 %</td>
</tr>
<tr>
<td>Medicare Managed Care</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td>Medicaid</td>
<td>11</td>
<td>9</td>
</tr>
<tr>
<td>Medicaid Managed Care</td>
<td>14</td>
<td>15</td>
</tr>
<tr>
<td>Blue Cross</td>
<td>22</td>
<td>26</td>
</tr>
<tr>
<td>Managed Care</td>
<td>24</td>
<td>24</td>
</tr>
<tr>
<td>Commercial</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Self-pay</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>100 %</strong></td>
<td><strong>100 %</strong></td>
</tr>
</tbody>
</table>

Products sponsored by Blue Cross Blue Shield of Illinois, the largest health insurer in the market, accounted for 47% and 52% of managed care net patient accounts receivable as of June 30, 2019 and 2018, respectively, and 22% and 26%, respectively, of total patient accounts receivable of Rush.
14. COMMITMENTS AND CONTINGENCIES

Professional Liability

Rush maintains insurance programs, including both self-insured and purchased insurance arrangements, for certain professional liability claims. Self-insured risks are retained in varying amounts according to policy year and entity. For the period December 9, 2017 to December 15, 2018, Rush maintained a general liability self-insurance risk of $5 million each and every claim, and a professional liability self-insurance risk of $10 million each and every claim, with a $10 million annual aggregate buffer, excess the $10 million. For the period from December 15, 2018 to December 15, 2019, RUMC maintained a general liability self-insurance risk of $5 million each and every claim, and a professional liability self-insurance risk of $10 million each and every claim, with a $15 million annual aggregate buffer, excess the $10 million. The December 15, 2018 to December 15, 2019 self-insured retentions are now uniform across the Rush System for Health, with Rush Copley paying its own self-insured retention as part of this overall self-insured retention. Rush System for Health also maintains excess liability insurance coverage with combined limits of $130 million per occurrence and in the aggregate for general liability, professional liability, and other lines of liability coverage for the period from December 15, 2018 to December 15, 2019. The excess liability insurance increased from the 2017-2018 period, where the overall limits were $120 million. Rush has an established irrevocable trust fund to pay claims and related costs, which is recorded within the self-insurance trust in the accompanying consolidated balance sheets.

Starting on January 1, 2010, RCMC implemented a self-insurance program for professional and general liability claims for claims not covered under the Chicago Hospital Risk Pooling Program. Self-insured risks are retained at $2,000 per claim and $10,000 annual aggregate with a $1,000 per claim and $1,000 aggregate buffer. RCMC also maintains excess liability insurance coverage with combined limits of $35,000 per claim and in the aggregate. Amounts above specified self-insured limits are insured through purchased insurance policies. Insurance is purchased on a claims-made basis. RCMC has established an account to pay claims and related costs.

Rush has employed an independent actuary to estimate the ultimate costs of claim settlements. Self-insured liabilities are based on the actuarial estimate of losses using Rush’s actual payout patterns and various other assumptions. Rush’s self-insured liabilities of $247,930 and $211,920 as of June 30, 2019 and 2018, respectively, are recorded as noncurrent and current liabilities in the accompanying consolidated balance sheets, as appropriate, and based on the estimated present value of self-insured claims that will be settled in the future. If the present value method was not used, Rush’s liability for self-insured claims would be approximately $21,980 and $20,971 higher than the amounts recorded in the consolidated balance sheets as of June 30, 2019 and 2018, respectively. The discount rates used in calculating the present value by organization was 4% for fiscal years ended June 30, 2019 and 2018. Insurance recoveries are presented separately within noncurrent and current assets in the accompanying consolidated balance sheets, as appropriate. As of June 30, 2019 and 2018, no insurance recoveries were recorded.

Rush is subject to various other regulatory investigations, legal proceedings, and claims that are incidental to its normal business activities. In the opinion of management, the amount of ultimate liability with respect to professional liability matters and other actions will not have a material adverse effect on the consolidated financial position or results of operations of Rush.
Obligations under Operating Leases

Rush is party to various noncancelable operating leases with third parties. Rental expense was approximately $37,851 and $33,257 for the years ended June 30, 2019 and 2018, respectively, and was included in supplies, utilities, and other expenses in the accompanying consolidated statements of operations and changes in net assets. Total minimum payments under noncancelable operating leases as of June 30, 2019, are as follows:

<table>
<thead>
<tr>
<th>Years Ending</th>
<th>June 30</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>$31,016</td>
</tr>
<tr>
<td>2021</td>
<td>$27,331</td>
</tr>
<tr>
<td>2022</td>
<td>$25,247</td>
</tr>
<tr>
<td>2023</td>
<td>$21,405</td>
</tr>
<tr>
<td>2024</td>
<td>$18,149</td>
</tr>
<tr>
<td>Thereafter</td>
<td>$65,135</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$188,283</strong></td>
</tr>
</tbody>
</table>

On December 29, 2017, Rush entered into a sale leaseback transaction over two properties. The sale resulted in cash proceeds of $76,582, a gain on sale of $20,927 recorded within other operating revenue of the accompanying consolidated statement of operations and a deferred gain on sale of $36,708 recorded within other liabilities of the accompanying consolidated balance sheet. RUMC will lease the space for ten years with future lease payments totaling $42,224 through December 2027.

15. UNCONDITIONAL PROMISES TO CONTRIBUTE

Included in assets limited by donor or time restriction are the following unconditional promises to contribute as of June 30, 2019 and 2018:

<table>
<thead>
<tr>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unconditional promises to contribute before unamortized discount and allowance for uncollectibles</td>
<td>$30,815</td>
</tr>
<tr>
<td>Less unamortized discount</td>
<td>(816)</td>
</tr>
<tr>
<td>Less allowance for uncollectibles</td>
<td>(3,600)</td>
</tr>
<tr>
<td><strong>Net unconditional promises to contribute</strong></td>
<td><strong>$26,399</strong></td>
</tr>
</tbody>
</table>

**Amounts due in:**

<table>
<thead>
<tr>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than one year</td>
<td>$11,886</td>
</tr>
<tr>
<td>One to five years</td>
<td>17,329</td>
</tr>
<tr>
<td>More than five years</td>
<td>1,600</td>
</tr>
<tr>
<td><strong>Total unconditional promises to contribute</strong></td>
<td><strong>$30,815</strong></td>
</tr>
</tbody>
</table>
16. NET ASSETS

Net assets without donor restrictions consist of the following as of June 20, 2019 and 2018:

<table>
<thead>
<tr>
<th>Net Assets Without Donor Restrictions</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-Board designated</td>
<td>$1,714,042</td>
<td>$1,644,786</td>
</tr>
<tr>
<td>Board designated</td>
<td>13,026</td>
<td>7,988</td>
</tr>
<tr>
<td>Total net assets without donor restrictions</td>
<td>$1,727,068</td>
<td>$1,652,774</td>
</tr>
</tbody>
</table>

Net assets with donor restrictions were available for the following purposes as of June 30, 2019 and 2018:

<table>
<thead>
<tr>
<th>Net Assets With Donor Restrictions</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Restricted for specified purpose:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Construction and purchase of equipment</td>
<td>$28,492</td>
<td>$1,111</td>
</tr>
<tr>
<td>Health education</td>
<td>22,772</td>
<td>16,644</td>
</tr>
<tr>
<td>Research, charity and other</td>
<td>438,326</td>
<td>415,555</td>
</tr>
<tr>
<td>Unappropriated endowment appreciation available for operations</td>
<td>64,347</td>
<td>63,555</td>
</tr>
<tr>
<td>Total funds designated for specified purpose</td>
<td>$553,937</td>
<td>$496,865</td>
</tr>
<tr>
<td>Endowments, perpetual in nature, the income from which is expendable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>for the following specified purposes:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health education</td>
<td>$174,361</td>
<td>$172,174</td>
</tr>
<tr>
<td>Research, charity and other</td>
<td>69,900</td>
<td>36,465</td>
</tr>
<tr>
<td>Operations</td>
<td>39,479</td>
<td>72,031</td>
</tr>
<tr>
<td>Total endowment net assets</td>
<td>283,740</td>
<td>280,670</td>
</tr>
<tr>
<td>Total net assets with donor restrictions</td>
<td>$837,677</td>
<td>$777,535</td>
</tr>
</tbody>
</table>

During fiscal years 2019 and 2018, net assets were released from donor restrictions for purchasing property and equipment of $16,804 and $1,919, respectively, and incurring expenses of $43,828 and $46,775, respectively, both of which satisfied the restricted purposes of the donors. Net assets released from restriction used in operations are included in other revenue in the accompanying consolidated statements of operations and changes in net assets.

17. JOINT VENTURES AND OTHER AFFILIATIONS

Investments in unconsolidated joint ventures, accounted for on the equity method, totaled $5,162 and $5,911 as of June 30, 2019 and 2018, respectively, and are included in other assets in the accompanying consolidated balance sheets. Income recognized from these joint ventures, reported in other revenue, was $1,513 and $1,588 during the years ended June 30, 2019 and 2018, respectively.

Rush has a majority interest in Rush Health and a majority representation on the Board of Trustees as of June 30, 2019. The addition of RCMC to the network resulted in a restructuring of the governance and membership structure of Rush Health. Rush has recorded equity in Rush Health based on membership interest of 56% or $4,256 and $3,746 as of June 30, 2019 and 2018, respectively. Rush has elected not to consolidate its interest in Rush Health, as it expects control to be temporary and believes the effects of consolidation to be immaterial.

18. FUNCTIONAL EXPENSES

The consolidated financial statements present certain expenses that are attributed to more than one program or supporting function. Operating expenses directly attributable to a specific functional area are reported as expenses of
those functional areas. Certain expenses are attributable to more than one functional area, and are therefore allocated on a reasonable basis that is consistently applied. Employee benefits are allocated based on factors of either salary expenses or hours worked. General and administrative expenses primarily include legal, finance and human resources activities. Overhead costs that include items such as professional services, office expenses, information technology, interest, insurance, occupancy and other similar expenses are allocated on a variety of factors, including relative costs, square footage, full-time equivalents, direct labor costs among others.

The expenses reported in the consolidated statement of operations for the year ended June 30, 2019, supported the following programs and functions:

<table>
<thead>
<tr>
<th></th>
<th>Healthcare Services</th>
<th>Academic &amp; Research Activity</th>
<th>General &amp; Administrative Support</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salaries, Wages &amp; Employee Benefits</td>
<td>$ 1,064,464</td>
<td>$ 153,106</td>
<td>$ 154,898</td>
<td>$ 1,372,468</td>
</tr>
<tr>
<td>Supplies, Utilities &amp; Other</td>
<td>647,452</td>
<td>94,862</td>
<td>45,536</td>
<td>787,850</td>
</tr>
<tr>
<td>Insurance</td>
<td>53,347</td>
<td>-</td>
<td>2,879</td>
<td>56,226</td>
</tr>
<tr>
<td>Purchased Services</td>
<td>155,558</td>
<td>7,919</td>
<td>45,541</td>
<td>209,018</td>
</tr>
<tr>
<td>Depreciation and Amortization</td>
<td>125,989</td>
<td>-</td>
<td>910</td>
<td>126,899</td>
</tr>
<tr>
<td>Interest</td>
<td>22,741</td>
<td>-</td>
<td>1,424</td>
<td>24,165</td>
</tr>
<tr>
<td>Total</td>
<td>$ 2,069,551</td>
<td>$ 255,887</td>
<td>$ 251,188</td>
<td>$ 2,576,626</td>
</tr>
</tbody>
</table>

19. GOODWILL

The changes in the carrying amount of goodwill for the years ended June 30, 2019 and 2018, were as follows:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beginning balance</td>
<td>$ 20,383</td>
<td>$ 20,383</td>
</tr>
<tr>
<td>Acquisition of goodwill</td>
<td>347</td>
<td>-</td>
</tr>
<tr>
<td>Ending balance</td>
<td>$ 20,730</td>
<td>$ 20,383</td>
</tr>
</tbody>
</table>

20. LIQUIDITY

Rush’s financial assets available within one year of the consolidated balance sheet date for general expenditures are as follows:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Current Assets:</strong></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$ 118,939</td>
</tr>
<tr>
<td>Accounts receivable for patient services</td>
<td>393,045</td>
</tr>
<tr>
<td>Other accounts receivable</td>
<td>40,451</td>
</tr>
<tr>
<td>Other current assets</td>
<td>20,327</td>
</tr>
<tr>
<td>Total current assets</td>
<td>572,762</td>
</tr>
<tr>
<td><strong>Investments:</strong></td>
<td>$ 1,153,989</td>
</tr>
<tr>
<td><strong>Total:</strong></td>
<td>$ 1,726,751</td>
</tr>
</tbody>
</table>
Rush has a policy to structure its financial assets to be available as its general expenditures, liability and other obligations come due. Certain other current assets within the accompanying consolidated balance sheet have been excluded from the liquidity table above due to the inability to either liquidate those assets or use them for general expenditures and other obligations, such as prepaid assets, grant related receivables and tuition loan receivables. As described in Note 7, Rush’s endowment consists of donor restricted funds established for a variety of purposes, with income from endowments being restricted for specific purposes. The Finance Committee of the Board of Trustees approves an annual endowment spending rate to be used for general purposes. As described in Note 9, Rush also has a $75 million line of credit available for working capital

*****
SUPPLEMENTAL SCHEDULES
INDEPENDENT AUDITORS’ REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING
AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL
STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT AUDITING STANDARDS

To the Board of Trustees of Rush System for Health:

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in Government Auditing Standards issued by the Comptroller General of the United States, the financial statements of Rush System for Health (the “System” or “Rush”), as of and for the year ended June 30, 2019, and the related notes to the financial statements, which collectively comprise Rush’s basic financial statements, and have issued our report thereon dated October 25, 2019.

Internal Control over Financial Reporting

In planning and performing our audit of the financial statements, we considered Rush’s internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinions on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of Rush’s internal control. Accordingly, we do not express an opinion on the effectiveness of Rush’s internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the Rush’s financial statements will not be prevented, or detected and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether Rush’s financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under Government Auditing Standards.
Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Rush’s internal control or on compliance. This report is an integral part of an audit performed in accordance with Government Auditing Standards in considering Rush’s internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Deloitte & Touche LLP

October 25, 2019
INDEPENDENT AUDITORS’ REPORT ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM AND REPORT ON INTERNAL CONTROL OVER COMPLIANCE IN ACCORDANCE WITH OMB UNIFORM GUIDANCE

To the Board of Trustees of Rush System for Health:

Report on Compliance for Each Major Federal Program

We have audited Rush System for Health’s (the “System” or “Rush”) compliance with the types of compliance requirements described in the OMB Compliance Supplement that could have a direct and material effect on its major federal program for the year ended June 30, 2019. Rush’s major federal program is identified in the summary of auditor’s results section of the accompanying schedule of findings and questioned costs.

Management’s Responsibility

Management is responsible for compliance with federal statutes, regulations, and the terms and conditions of federal awards applicable to its federal programs.

Auditor’s Responsibility

Our responsibility is to express an opinion on compliance for Rush’s major federal program based on our audit of the types of compliance requirements referred to above.

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about Rush’s compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for the major federal program. However, our audit does not provide a legal determination of Rush’s compliance.

Opinion on Compliance for Each Major Federal Program

In our opinion, Rush complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on its major federal program for the year ended June 30, 2019.

Report on Internal Control over Compliance

Management of Rush is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered Rush’s internal control over compliance with the types of requirements that could have a direct and material effect on its major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for its major federal program and to test
and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of Rush’s internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Deloitte & Touche LLP

December 18, 2019
<table>
<thead>
<tr>
<th>Federal Grantor/Pass-Through Grantor/Program or Cluster Title</th>
<th>Federal CFDA Number</th>
<th>Federal Grantor/Pass-Through Grantor's Number</th>
<th>Federal Expenditures</th>
<th>Subrecipients</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RESEARCH AND DEVELOPMENT</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S. Department of Health and Human Services:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>National Institute of Health</td>
<td>93.RD</td>
<td></td>
<td>55,437,414</td>
<td>10,597,082</td>
</tr>
<tr>
<td>Passed through Blood Research of Wisconsin:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comparative Effectiveness in the Diagnosis of VWD</td>
<td>93.839 R01HL112614</td>
<td></td>
<td>3,400</td>
<td></td>
</tr>
<tr>
<td>Passed through University of Arizona:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Identifying therapeutic targets that confer synaptic resilience to Alzheimer’s disease</td>
<td>93.866 R01AG061800</td>
<td></td>
<td>68,319</td>
<td></td>
</tr>
<tr>
<td>Passed through University of Arizona:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Building a Novel Predictive Networks for High-throughput, In-silico Key Driver Prioritization to Enhance Drug Target Discovery in Amp-AD and M2OVE-AD</td>
<td>93.866 RF1AG057457</td>
<td></td>
<td>10,910</td>
<td></td>
</tr>
<tr>
<td>Passed through University of Hawaii:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Profiling genome-wide circulating ncRNAs for the early detection of lung cancer</td>
<td>93.394 R01CA223490</td>
<td></td>
<td>3,299</td>
<td></td>
</tr>
<tr>
<td>Passed through University of Mississippi:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jackson Heart Study Coordinating Center</td>
<td>93.RD</td>
<td>HH5N268201800010</td>
<td>3,787</td>
<td></td>
</tr>
<tr>
<td>Passed through Van Andel Research Institute:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Promoting survival of dopamine neurons in models of Parkinson disease using a novel transcriptional regulator</td>
<td>93.853 R21NS105436</td>
<td></td>
<td>5,362</td>
<td></td>
</tr>
<tr>
<td>Combining synucleinopathy and mitochondrial deficits in a novel mouse model of Parkinsons disease</td>
<td>93.853 R21NS106078</td>
<td></td>
<td>21,376</td>
<td></td>
</tr>
<tr>
<td>Passed through Ohio State:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IFITM-mediated inhibition of HIV infection and viral countermeasures</td>
<td>93.855 R01AI112381</td>
<td></td>
<td>16,032</td>
<td></td>
</tr>
<tr>
<td>Passed through University of Utah:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Circadian and sleep pathways to cardiometabolic disease risk:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Passed through University of Texas:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A Randomized Recruitment Intervention /RECRUIT</td>
<td>93.307 U24MD006941</td>
<td></td>
<td>8,829</td>
<td></td>
</tr>
<tr>
<td>Passed through Loyola University:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Host Response to Pessaries in teh Postmenopausal Vagina</td>
<td>93.866 R03AG0505933</td>
<td></td>
<td>18,137</td>
<td></td>
</tr>
<tr>
<td>Passed through University of Cincinnati:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atrial Cardiopathy and Antithrombotic Drugs in prevention After cryptogenistroke ARCADIA</td>
<td>93.853 U01NS095869</td>
<td></td>
<td>1,491</td>
<td></td>
</tr>
<tr>
<td>Passed through Metropolitan Chicago Healthcare Council:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCHC - Chicago Hospital Council Subaward Agreement</td>
<td>93.889 12102602</td>
<td></td>
<td>55,000</td>
<td></td>
</tr>
<tr>
<td>Passed through CDC:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Candida auris, an emerging fungal pathogen of high concern</td>
<td>93.RD</td>
<td>75D303118CD02900</td>
<td>87,554</td>
<td></td>
</tr>
<tr>
<td>Genomic Epidemiology of Community-Onset Invasive USA3 MRSA Infections</td>
<td>93.RD 75D303118CD02923</td>
<td></td>
<td>24,326</td>
<td></td>
</tr>
<tr>
<td>Development of reproducible, quantitative methods based on shotgun metagenome sequencing for assessment of risk of microbial transmission</td>
<td>93.084 75D303118CD02915</td>
<td></td>
<td>11,547</td>
<td></td>
</tr>
<tr>
<td>Passed through Hektoen Institute:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chicago Consortium for the Women’s Interagency HIV Study</td>
<td>93.855 U01AI034993</td>
<td></td>
<td>113,542</td>
<td></td>
</tr>
<tr>
<td>Chicago WHS Consortium - WHS V</td>
<td>93.855 U01AI034993</td>
<td></td>
<td>27,146</td>
<td></td>
</tr>
<tr>
<td>The Contribution of Sleep and Circadian Disruption to Kynurenine Pathway Activation and Cardiometabolic Risk in Women with HIV</td>
<td>93.838 HL142116-01</td>
<td></td>
<td>10,892</td>
<td></td>
</tr>
<tr>
<td>Passed through Columbia University:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interdisciplinary Research to Understand the Interplay of Diabetes Cerebrovascular Disease and Alzheimer’s C Pathway Discovery, Validation for Alzheimer’s Disease and Compound Identificationfor Alzheimer’s Disease</td>
<td>93.866 RF1AG051556</td>
<td></td>
<td>11,402</td>
<td></td>
</tr>
<tr>
<td>Pathway Discovery, Validation and Compound Identificationfor Alzheimer’s Disease and NIA Late Onset of Alzheimer’s Disease (LOAD)Family Based Study</td>
<td>93.866 U01AG046152</td>
<td></td>
<td>457,037</td>
<td></td>
</tr>
<tr>
<td>Pathway Discovery, Validation and Compound Identificationfor Alzheimer’s Disease and Compound Identificationfor Alzheimer’s Disease</td>
<td>93.866 U01AG046152</td>
<td></td>
<td>82,750</td>
<td></td>
</tr>
<tr>
<td>Pathway Discovery, Validation and Compound Identificationfor Alzheimer’s Disease and Compound Identificationfor Alzheimer’s Disease</td>
<td>93.866 U24AG056270</td>
<td></td>
<td>45,939</td>
<td></td>
</tr>
<tr>
<td>Influence of Genotype on Monocyte and Microglia Phenotypeand Function in PD</td>
<td>93.866 R56 NS089674</td>
<td></td>
<td>98,464</td>
<td></td>
</tr>
<tr>
<td>Deconstructing and modeling the single cell architecture of the Alzheimer brain</td>
<td>93.866 1RF1AG057473</td>
<td></td>
<td>67,803</td>
<td></td>
</tr>
<tr>
<td>Convergence of myeloid susceptibility protein function in Alzheimer’s disease</td>
<td>93.866 R01AG058852</td>
<td></td>
<td>48,329</td>
<td></td>
</tr>
<tr>
<td>A Randomized Multicenter Clinical Trial of Unruptured Brain Arteriovenous Malformations</td>
<td>93.853 U01 NS051483</td>
<td></td>
<td>2,181</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Federal Grantor/Pass-Through Grantor/Program or Cluster Title</th>
<th>CFDA Number</th>
<th>Subrecipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Passed through Jaeb Center for Health Research:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peripheral DR Lesions on Ultrawide-field Fundus Images and Risk of Diabetic Retinopathy Worsening Over time (Protocol AA)</td>
<td>93.867 U10 EY014231</td>
<td>567</td>
</tr>
<tr>
<td>Passed through Northwestern University:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin D add-on therapy enhances Corticosteroid responsiveness in Asthma</td>
<td>93.837 U10 HL098096</td>
<td>176,109</td>
</tr>
<tr>
<td>Knee OA: Predicators and Outcomes of Physical Inactivity-Activity Transitions</td>
<td>93.846 R01AR054155</td>
<td>4,102</td>
</tr>
<tr>
<td>NIAMS Multidisciplinary Clinical Research Center</td>
<td>93.846 P60AR044664</td>
<td>1,408</td>
</tr>
<tr>
<td>A Phase 3, Double-Blind, Placebo-Controlled, Parallel Group Study of Isradipine as a Disease Modifying Agent in Patients with Early Parkinson’s Disease / STEADY-P03</td>
<td>93.853 U01 NS080818</td>
<td>118,500</td>
</tr>
<tr>
<td>Chicago Clinical Trials Unit</td>
<td>93.855 UM A069471</td>
<td>367,724</td>
</tr>
<tr>
<td>SPORE in Prostate Cancer</td>
<td>93.397 P50CA180995</td>
<td>45,547</td>
</tr>
<tr>
<td>Great Lakes Practive Transformation Network 5345/L1CMS331444</td>
<td>93.638 1L1CMS331444</td>
<td>1,320</td>
</tr>
<tr>
<td>Food Allergy Outcomes Related to White and AfricanAmerican Racial Differences (FORWARD)</td>
<td>93.855 R01AI030348</td>
<td>177,656</td>
</tr>
<tr>
<td>A Family Genetic Study of Language in Autism</td>
<td>93.173</td>
<td>50,529</td>
</tr>
<tr>
<td>Knee OA: Predicators and Outcomes of Physical Inactivity-Activity Transitions</td>
<td>93.846</td>
<td>28</td>
</tr>
<tr>
<td>Latinos vs Non-Latinos: Disparities in Advance Care Planning &amp; End-of-Life Care</td>
<td>93.307</td>
<td>1,467</td>
</tr>
<tr>
<td>Synaptic Substrates of Age-Dependent Memory Deficits</td>
<td>93.866 2RF1AG017139</td>
<td>246,557</td>
</tr>
<tr>
<td>Effect of Unilateral and Bilateral STN Stimulation on Eye-Hand Coordination</td>
<td>93.853 R01NS02950</td>
<td>18,700</td>
</tr>
<tr>
<td>Core Center for Clinical Research at NU</td>
<td>93.846 P30AR072579</td>
<td>16,361</td>
</tr>
<tr>
<td>Center for chronic pain and drug abuse</td>
<td>93.279</td>
<td>4,523</td>
</tr>
<tr>
<td>Molecular mechanisms underlying behavioral and psychological symptoms in Alzheimer’s disease</td>
<td>93.866 R01AG062249</td>
<td>79,641</td>
</tr>
<tr>
<td>Lupus Intervention Fatigue Trial (LIFT)</td>
<td>93.846 R01AR071091</td>
<td>1,467</td>
</tr>
<tr>
<td>Passed through University of Illinois:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acceleration PrEP Diffusion through Network Change Agents</td>
<td>93.855 R01 AI207070</td>
<td>3,734</td>
</tr>
<tr>
<td>Chicago Center for Youth Violence Prevention</td>
<td>93.136 U01CE02712</td>
<td>42,697</td>
</tr>
<tr>
<td>ITM 2.0: Advancing Translational Science in Metropolitan Chicago</td>
<td>93.350 K24HL122387</td>
<td>394,363</td>
</tr>
<tr>
<td>ITM 2.0: Advancing Translational Science in Metropolitan Chicago</td>
<td>93.350 U11TR002389</td>
<td>799,151</td>
</tr>
<tr>
<td>ITM 2.0: Advancing Translational Science in Metropolitan Chicago</td>
<td>93.350 U11TR002389</td>
<td>60,136</td>
</tr>
<tr>
<td>ITM 2.0: Advancing Translational Science in Metropolitan Chicago</td>
<td>93.350 U11TR002389</td>
<td>13,397</td>
</tr>
<tr>
<td>Chicago Metropolitan Asthma Consortium for Severe/Exacerbation-prone Asthma</td>
<td>93.838 R01HL1139125</td>
<td>38,000</td>
</tr>
<tr>
<td>CTSA K12 Examining an Adaptive Telehealth Intervention for Young Children with ASD</td>
<td>93.350 K24HL122387</td>
<td>(68,833)</td>
</tr>
<tr>
<td>Evaluating a Self-Care Intervention for Older Adults using Agent-based Modeling</td>
<td>93.866 R01AG047869</td>
<td>7,181</td>
</tr>
<tr>
<td>The role of elevated BIN1 in Alzheimer’s disease</td>
<td>93.866 R01AG056061</td>
<td>85,536</td>
</tr>
<tr>
<td>Illinois Precision Medicine Consortium</td>
<td>93.310 OT2OD026557</td>
<td>1,194,838</td>
</tr>
<tr>
<td>Passed through Yale University:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leadership Education in Neurodevelopmental and Related Disorders Training Program</td>
<td>93.110 T33MC11047</td>
<td>5,022</td>
</tr>
<tr>
<td>The Asthma Action at Easte Trial</td>
<td>93.838 R01 HL123797</td>
<td>25,583</td>
</tr>
<tr>
<td>The Effect of Penile Microbiome on BV, GUO and Genital Epithelial Trauma</td>
<td>93.855 R01 AI103069</td>
<td>41,038</td>
</tr>
<tr>
<td>Plasticity Circuits in Alzheimer’s Disease</td>
<td>93.866 R01 AG035370</td>
<td>39,808</td>
</tr>
<tr>
<td>The Effect of Alcohol on Retinal Photic Signaling to the Human Circadian System</td>
<td>93.273 R01AA023839</td>
<td>59,200</td>
</tr>
<tr>
<td>Integrated Mechanisms of Cardiac Maladaptation</td>
<td>93.837 R01HL062426</td>
<td>105,687</td>
</tr>
<tr>
<td>Diet Modulation of Bacterial Sugar &amp; Bile Acid Metabolism and Colon Cancer Risk</td>
<td>93.393 1R15CA204808</td>
<td>153,412</td>
</tr>
<tr>
<td>Improving White Matter Integrity with Thyroid Hormone</td>
<td>93.853 R21NS05723</td>
<td>7,470</td>
</tr>
<tr>
<td>Mediterranean Diet, Weight Loss, and Cognition in Obese Older Adults</td>
<td>93.837 R01HL129153</td>
<td>16,880</td>
</tr>
<tr>
<td>Leadership Education in Neurodevelopmental and Related Disabilities Training Program</td>
<td>93.110 T33MC11047-09-00</td>
<td>11,240</td>
</tr>
<tr>
<td>Center for Health Equity Research (CHER)</td>
<td>93.307 U54MD001253</td>
<td>15,778</td>
</tr>
<tr>
<td>AHEC Point of Service Maint &amp; Enhancement</td>
<td>93.107 U77HP26847</td>
<td>33,364</td>
</tr>
<tr>
<td>Passed through Westat Inc:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NICHID International and domestic Pediatric and Maternal HIV Studies Coordinating Center</td>
<td>93.93 R01NS06736</td>
<td>15,399</td>
</tr>
<tr>
<td>Molecular Networks Underlying Resilience to Alzheimer’s Disease Among APOE E4 Carriers</td>
<td>93.866 R01AG057912</td>
<td>94,447</td>
</tr>
<tr>
<td>Passed through Yale University:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Pathological Study of Cognitive Impairment in Essential Tremor</td>
<td>93.853 R01 NS06736</td>
<td>15,399</td>
</tr>
<tr>
<td>NIAID (DHHS) Contract:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Virology Quality Assurance Program</td>
<td>93.93 R01AG057912</td>
<td>74,644</td>
</tr>
</tbody>
</table>
| (Continued)
<table>
<thead>
<tr>
<th>Federal Grantor/Pass-Through</th>
<th>Program or Cluster Title</th>
<th>CFDA Number</th>
<th>Federal Grantor/Pass-Through Federal Grantor/Program or Cluster Title</th>
<th>Number</th>
<th>Expenditures</th>
<th>Subrecipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Virology Quality Assurance Program</td>
<td>93.RD</td>
<td>HHSN272201200023C</td>
<td>261,401</td>
<td>261,401</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Virology Quality Assurance Program</td>
<td>93.RD</td>
<td>HHSN272201200023C</td>
<td>106,281</td>
<td>106,281</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Virology Quality Assurance Program</td>
<td>93.RD</td>
<td>HHSN272201200023C</td>
<td>66,312</td>
<td>66,312</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Virology Quality Assurance Program</td>
<td>93.RD</td>
<td>HHSN272201200023C</td>
<td>702,696</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Passed through University of Miami:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mechanisms of Early Recurrence in Intracranial Atherosclerotic Disease</td>
<td>93.853</td>
<td>R01 NS084288</td>
<td>1,962</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Passed through University of California: USC, UC Davis, California Institute of Technology, Children Hospital LA, UCLA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A Cognitive Test Battery for Intellectual Disabilities</td>
<td>93.865</td>
<td>R01 HD076189</td>
<td>127,878</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alzheimer's Disease Neuroimaging Initiative 2 (ADNI2)</td>
<td>93.866</td>
<td>U01AG024904</td>
<td>94,699</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alzheimer's Disease Cooperative Study - A4 Study</td>
<td>93.866</td>
<td>U19 AG010483</td>
<td>5,714</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AKAP-dependent regulation of Cardiac SR Ca handling</td>
<td>93.837</td>
<td>R01HL138812</td>
<td>85,659</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD4+ T-cell counts and CD4+ T-cell dysfunction</td>
<td>93.847</td>
<td>R01DK109720</td>
<td>300,792</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Racial Differences in Decision Making among Older Adults</td>
<td>93.866</td>
<td>R01AG055430</td>
<td>379,425</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Higher Precision Human and Mouse Transcripts</td>
<td>93.172</td>
<td>UM1HG009443</td>
<td>26,079</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonlinear Models of Cognition Predicting AD and non-AD in a Biracial Population Sample</td>
<td>93.866</td>
<td>R01AG051635</td>
<td>59,212</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory Center, AIDS Clinical Trials Group (ACTG) LC2/3</td>
<td>93.855</td>
<td>U01AI106701</td>
<td>59,634</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alzheimer's Clinical Trial Consortium (ACTC)</td>
<td>93.866</td>
<td>U44AG057437</td>
<td>193,457</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Passed through University of Washington:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>National Alzheimer's Coordinating Center</td>
<td>93.866</td>
<td>U01AG016976</td>
<td>(24,749)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADNI Psychometrics</td>
<td>93.866</td>
<td>R01AG029672</td>
<td>32,176</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mechanisms of Psychosocial Treatments for Chronic Low Back Pain</td>
<td>93.213</td>
<td>R01AT08559</td>
<td>21,203</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Passed through Emory University:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Studies of Dystonia and Related Disorders</td>
<td>93.853</td>
<td>U54 NS065701</td>
<td>(2,440)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discovery of Novel Proteomic Targets for Treatment of Alzheimer's Disease</td>
<td>93.866</td>
<td>U01 AG046161</td>
<td>90,507</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testing Tel-Savvy, an Online Psychoeducation Program for Informal Alzheimer's Caregivers</td>
<td>93.866</td>
<td>R01AG054079</td>
<td>35,949</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Understanding the Molecular Mechanisms of Depression and Psychological Well-being in Alzheimer's Disease</td>
<td>93.866</td>
<td>R01AG056533</td>
<td>102,803</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Building a High-resolution Multi-Omic AD Interactome with the A4-AD and MZO-AD Projects</td>
<td>93.866</td>
<td>R01AG057470</td>
<td>55,368</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain - Plasma Proteomics Biomarker Discovery and Validation in US and UK</td>
<td>93.866</td>
<td>RF1AG057471</td>
<td>45,593</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Computational Prediction and Functional Validation of Novel Risk Loci in Alzheimer's Disease</td>
<td>93.866</td>
<td>R56AG060757</td>
<td>36,600</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Computational Prediction and Functional Validation of Novel Epigenetic Risk Loci in Alzheimer's Disease</td>
<td>93.866</td>
<td>R56AG062256</td>
<td>46,122</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Passed through Albert Einstein College of Medicine:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Role of Innate Immunity in HIV-related vascular disease; biomarkers and mechanisms</td>
<td>93.837</td>
<td>R01 HL126543</td>
<td>2,082</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Integrated Analysis of CVD Risk in HIV-Gut Microbiota, Immune Function and Metabolites</td>
<td>93.837</td>
<td>R01HL140976</td>
<td>11,062</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Passed through John Hopkins:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multi Uveitis Steroid treatment trial</td>
<td>93.867</td>
<td>U10 EY024527</td>
<td>1,575</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Effects of Glucocorticoids on Cognitive Functioning in HIV-infected Women</td>
<td>93.242</td>
<td>R01MH113512</td>
<td>11,734</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LOC - IMPAACT Leadership Group</td>
<td>93.855</td>
<td>UM1AA066832</td>
<td>190,828</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Translational Research in Neuro-AIDS Mental Health</td>
<td>93.242</td>
<td>R55MH080661</td>
<td>16,806</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HOPE In Action: A clinical trial of HIV-to-HIV deceased donor kidney transplantation</td>
<td>93.855</td>
<td>U01AI134591</td>
<td>194</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Passed through Brigham and Women's Hospital:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory Center, AIDS Clinical Trials Group (ACTG)</td>
<td>93.855</td>
<td>U1M AI0106701</td>
<td>115,303</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AIDS Clinical Trial Group Network</td>
<td>93.855</td>
<td>AI068636</td>
<td>154,669</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AIDS Clinical Trial Group Network</td>
<td>93.855</td>
<td>AI068636</td>
<td>131,646</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neuropathology for Disrupted Multiscale Activity Control in Alzheimer's Disease</td>
<td>93.866</td>
<td>R01 AG048108</td>
<td>12,242</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fractal motor activity regulation and the risk for Alzheimer's disease in middle to old age adults</td>
<td>93.866</td>
<td>R01AG059867</td>
<td>17,512</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AIDS Clinical Trial Group</td>
<td>93.855</td>
<td>U51 AI068636-12</td>
<td>85,478</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leadership &amp; Operations Center (LOC) AIDS Clinical Trials Group (ACTG)</td>
<td>93.855</td>
<td>UM1AA068636-12</td>
<td>55,047</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neuropathy due disrupted multiscale activity control in Alzheimer's disease</td>
<td>93.866</td>
<td>R01AG048108</td>
<td>23,051</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACOSOG- A Phase III Prospective, Randomized Trial Comparing Laparoscopic Assisted Resection Versus Open Resection for Rectal Cancer</td>
<td>93.395</td>
<td>U01 CA076001</td>
<td>8,200</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
Passed through Massachusetts General Hospital:

<table>
<thead>
<tr>
<th>Grantor/Program or Cluster Title</th>
<th>CFDA Number</th>
<th>Federal Grantor/Pass-Through</th>
<th>Federal Expenditures</th>
<th>Subrecipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE</td>
<td>93.837</td>
<td>U01 HL23336</td>
<td>12,848</td>
<td></td>
</tr>
<tr>
<td>Recurrent Hemorrhagic Stroke in Minority Populations</td>
<td>93.853</td>
<td>R01NS093870</td>
<td>34,795</td>
<td></td>
</tr>
<tr>
<td>A randomized, double-blind, placebo-controlled trial of urate-elevating inosine treatment to</td>
<td>93.823</td>
<td>U01NS095025</td>
<td>81,762</td>
<td></td>
</tr>
<tr>
<td>slow clinical decline in early Parkinson disease.</td>
<td>93.847</td>
<td>R01DK093773</td>
<td>39,790</td>
<td></td>
</tr>
<tr>
<td>Coenzyme Q1 in Huntington's Disease</td>
<td>93.853</td>
<td>5 U01 NS052592</td>
<td>520</td>
<td></td>
</tr>
</tbody>
</table>

Passed through Great Lakes Hemophilia:

<table>
<thead>
<tr>
<th>Grantor/Program or Cluster Title</th>
<th>CFDA Number</th>
<th>Federal Grantor/Pass-Through</th>
<th>Federal Expenditures</th>
<th>Subrecipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regional Program</td>
<td>93.184</td>
<td>H30 MC24052</td>
<td>33,732</td>
<td></td>
</tr>
</tbody>
</table>

Passed through University of Florida:

<table>
<thead>
<tr>
<th>Grantor/Program or Cluster Title</th>
<th>CFDA Number</th>
<th>Federal Grantor/Pass-Through</th>
<th>Federal Expenditures</th>
<th>Subrecipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genome-wide Profiling of Brain DNA Hydroxymethylome in Alzheimer's Disease</td>
<td>93.866</td>
<td>RF1AG052476</td>
<td>151,069</td>
<td></td>
</tr>
<tr>
<td>Dignity Therapy RCT led by Nurses of Chaplains for Elderly Cancer Outpatients</td>
<td>93.395</td>
<td>RO1CA200867</td>
<td>73,886</td>
<td></td>
</tr>
<tr>
<td>Neuroimaging Biomarkers in Parkinsonism: Differentiating Subtypes and Tracking Disease Progression</td>
<td>93.853</td>
<td>U01NS102038</td>
<td>42,982</td>
<td></td>
</tr>
</tbody>
</table>

Passed through University of Pittsburgh:

<table>
<thead>
<tr>
<th>Grantor/Program or Cluster Title</th>
<th>CFDA Number</th>
<th>Federal Grantor/Pass-Through</th>
<th>Federal Expenditures</th>
<th>Subrecipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Signaling Mechanisms of Focal Adhesion Protein Kindlin-2 in Chondrogenesis</td>
<td>93.846</td>
<td>R01 AR068950</td>
<td>210,461</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular and HIV/AIDS Effect on Brain Structure/Function and Cognition</td>
<td>93.866</td>
<td>R01 AG038852</td>
<td>27,278</td>
<td></td>
</tr>
<tr>
<td>Translational Evaluation of Aging, Inflammation &amp; HIV In Lung Dysfunction</td>
<td>93.838</td>
<td>R01 HL120308</td>
<td>86</td>
<td></td>
</tr>
<tr>
<td>SIV Pathogenesis in African Green Monkeys and Pigtailed Macaques</td>
<td>93.837</td>
<td>R01HL1371715-13A1</td>
<td>33,568</td>
<td></td>
</tr>
</tbody>
</table>

Passed through University of Michigan/Michigan State:

<table>
<thead>
<tr>
<th>Grantor/Program or Cluster Title</th>
<th>CFDA Number</th>
<th>Federal Grantor/Pass-Through</th>
<th>Federal Expenditures</th>
<th>Subrecipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nortriptyline-mediated attenuation of Alpha-Synuclein Pathology in Parkinson's Disease</td>
<td>93.853</td>
<td>R01 NS094460</td>
<td>295,567</td>
<td></td>
</tr>
<tr>
<td>Systems Biology of Clostridium Diffuse Infection</td>
<td>93.855</td>
<td>U01AI124255</td>
<td>219,512</td>
<td></td>
</tr>
<tr>
<td>Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD</td>
<td>93.853</td>
<td>U01NS110398</td>
<td>75,083</td>
<td></td>
</tr>
</tbody>
</table>

Passed through Vanderbilt University:

<table>
<thead>
<tr>
<th>Grantor/Program or Cluster Title</th>
<th>CFDA Number</th>
<th>Federal Grantor/Pass-Through</th>
<th>Federal Expenditures</th>
<th>Subrecipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduced Opioid Analgesic Requirements via Improved Endogenous Opioid Function</td>
<td>93.279</td>
<td>R01 DA037891</td>
<td>163,295</td>
<td></td>
</tr>
<tr>
<td>Genetic Drivers of Resilience to Alzheimer's Disease</td>
<td>93.866</td>
<td>R01AG059716</td>
<td>21,381</td>
<td></td>
</tr>
<tr>
<td>Neurprotective Effects of Vascular Endothelial Growth Factor in Alzheimer's Disease</td>
<td>93.866</td>
<td>R01AG061518</td>
<td>7,444</td>
<td></td>
</tr>
</tbody>
</table>

Passed through Sunnybrook Research Institute:

<table>
<thead>
<tr>
<th>Grantor/Program or Cluster Title</th>
<th>CFDA Number</th>
<th>Federal Grantor/Pass-Through</th>
<th>Federal Expenditures</th>
<th>Subrecipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sleep, Circadian Rhythms, and Mechanisms of Cognitive Decline in the Human Brain</td>
<td>93.866</td>
<td>R01AG052488</td>
<td>369,336</td>
<td></td>
</tr>
</tbody>
</table>

Passed thru Washington University:

<table>
<thead>
<tr>
<th>Grantor/Program or Cluster Title</th>
<th>CFDA Number</th>
<th>Federal Grantor/Pass-Through</th>
<th>Federal Expenditures</th>
<th>Subrecipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Washington University &amp; BIC Epicenter for Prevention of Healthcare Associated Infections</td>
<td>93.084</td>
<td>U54CX000482</td>
<td>114,627</td>
<td></td>
</tr>
<tr>
<td>Passed thru University of North Carolina at Chapel Hill:</td>
<td>93.866</td>
<td>R01 AG040034</td>
<td>33,056</td>
<td></td>
</tr>
<tr>
<td>Oxidative Stress and the Development of Osteoarthritis</td>
<td>93.866</td>
<td>R01 AG040034</td>
<td>33,056</td>
<td></td>
</tr>
<tr>
<td>The Role of Human Gut Microbiota in HIV-1 Rectal Acquisition, Replication and Pathogenesis</td>
<td>93.855</td>
<td>R01AI123010</td>
<td>18,309</td>
<td></td>
</tr>
</tbody>
</table>

Passed thru Harvard Pilgrim Health Care:

<table>
<thead>
<tr>
<th>Grantor/Program or Cluster Title</th>
<th>CFDA Number</th>
<th>Federal Grantor/Pass-Through</th>
<th>Federal Expenditures</th>
<th>Subrecipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety and Healthcare Epidemiology Prevention Research Development (SHEPheRD) Program CLUSTER -</td>
<td>93.823</td>
<td>2011-N-13526</td>
<td>955,628</td>
<td></td>
</tr>
<tr>
<td>Cytokines in Cancer in Humans with HIV/AIDS</td>
<td>93.866</td>
<td>U24 AG021886</td>
<td>22,322</td>
<td></td>
</tr>
<tr>
<td>Promoting Healing of Tendinopathies using Metabolic Stimulation</td>
<td>93.846</td>
<td>R01 AR0563144</td>
<td>94,997</td>
<td></td>
</tr>
</tbody>
</table>

Passed thru Gynecologic Oncology Group:

<table>
<thead>
<tr>
<th>Grantor/Program or Cluster Title</th>
<th>CFDA Number</th>
<th>Federal Grantor/Pass-Through</th>
<th>Federal Expenditures</th>
<th>Subrecipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gynecologic Oncology Group</td>
<td>93.395</td>
<td>27469-09</td>
<td>1,387</td>
<td></td>
</tr>
<tr>
<td>Passed through Baylor College of Medicine:</td>
<td>93.866</td>
<td>R01AG055061</td>
<td>60,745</td>
<td></td>
</tr>
<tr>
<td>Functional Validation of the CD14AP Susceptibility Network in Alzheimer's Disease</td>
<td>93.846</td>
<td>R01AR072562</td>
<td>82,055</td>
<td></td>
</tr>
<tr>
<td>Mechanisms of coupling linked skeletal muscle myopathies</td>
<td>93.866</td>
<td>R01 AG046174</td>
<td>51,690</td>
<td></td>
</tr>
<tr>
<td>Genome Engineering an iPSC Model of Alzheimer's Disease</td>
<td>93.866</td>
<td>R01 AG048056</td>
<td>28,401</td>
<td></td>
</tr>
</tbody>
</table>

Passed through Boston University/Boston Children's Hospital:

<table>
<thead>
<tr>
<th>Grantor/Program or Cluster Title</th>
<th>CFDA Number</th>
<th>Federal Grantor/Pass-Through</th>
<th>Federal Expenditures</th>
<th>Subrecipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Brain Transcriptome &amp; Lifetime Obesity Measures: The Framingham Study</td>
<td>93.847</td>
<td>R01DK092926</td>
<td>68,908</td>
<td></td>
</tr>
<tr>
<td>Development of Synaptopathies associated with TSC, PTEN and SHANK3</td>
<td>93.853</td>
<td>U54 NS02090</td>
<td>70,976</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Federal Grantor/Pass-Through Grantor/Program or Cluster Title</th>
<th>Federal CFDA Grantor/Pass-Through Grantor's Number</th>
<th>Federal Expenditures</th>
<th>Subrecipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Passed through Oregon Health and Science Institute:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ORCATECH Collaborative Aging (in Place) Research Using Technology (CART)</td>
<td>93.866 1U2CA5G054397-01</td>
<td>190,906</td>
<td></td>
</tr>
<tr>
<td>Personality and Health: A Longitudinal Study</td>
<td>93.866 R01AG020048</td>
<td>32,099</td>
<td></td>
</tr>
<tr>
<td>Passed through St. Joseph's Hospital and Medical Center:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurobiology and Cognitive Impairment of the Elderly</td>
<td>93.866 P01 AG014449</td>
<td>82,032</td>
<td></td>
</tr>
<tr>
<td>Passed through University of Iowa:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neuroendocrine Tumor Specialized Programs of Research Excellence (SPORE) in Human Cancer</td>
<td>93.397 P50CA74521</td>
<td>8,752</td>
<td></td>
</tr>
<tr>
<td>Passed through Rutgers University:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myocardial Ischemia and Transfusion MINT</td>
<td>93.839 SU01HL133817</td>
<td>1,183</td>
<td></td>
</tr>
<tr>
<td>Assisi Resource Centers for Minority Aging Research RCMAR</td>
<td>93.866 P30AG059304</td>
<td>3,915</td>
<td></td>
</tr>
<tr>
<td>Passed through Lurie Children's Hospital:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Employing eSBI in a Community-based HIV Testing Environment for at-risk Youth</td>
<td>93.279 R01 DA041071</td>
<td>80,886</td>
<td></td>
</tr>
<tr>
<td>Passed through University of Rochester:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cohort of HIV-Associated Seizures and Epilepsy in Zambia (CHASE): Scale Up and Expansion</td>
<td>93.853 R01NS094037</td>
<td>8,733</td>
<td></td>
</tr>
<tr>
<td>Passed through Wake Forest University Health Sciences:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Developing Research at the Interface of HIV and Aging</td>
<td>93.866 R24AG044325</td>
<td>91,508</td>
<td></td>
</tr>
<tr>
<td>Passed through NeuroNex- Novartis and Massachusetts General Hospital:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Effects of AFQ056 on Language Learning in Young Children with Fragile X Syndrome (FXS)</td>
<td>93.853 U01NS096767</td>
<td>76,101</td>
<td></td>
</tr>
<tr>
<td>Effects of AFQ056 on Language Learning in Young Children with Fragile X Syndrome (FXS)</td>
<td>93.853 U01NS096767</td>
<td>97,786</td>
<td></td>
</tr>
<tr>
<td>Passed through NCi- NCTN (ECOG, ALLIANCE, NRG, SWOG)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase III Trial of Enalustamide versus Enalustamide, Atriobterone and Prednisone for Castration Resistant Metastatic Prostate Cancer</td>
<td>93.RD A031201</td>
<td>212</td>
<td></td>
</tr>
<tr>
<td>Passed through Kaiser Foundation:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early Vascular Contributions to Dementia Risk in African-Americans</td>
<td>93.866 R01AG050782</td>
<td>7,552</td>
<td></td>
</tr>
<tr>
<td>Passed through IIT:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comprehensive Probabilistic Atlas of the Brain of Older Adults without Dementia</td>
<td>93.866 1R01AG052200</td>
<td>95,351</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
RUSH SYSTEM FOR HEALTH  
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS  
YEAR ENDED JUNE 30, 2019

<table>
<thead>
<tr>
<th>Federal Grantor/Pass-Through Grantor/Program or Cluster Title</th>
<th>Federal CFDA Number</th>
<th>Federal Grantor/Pass-Through Grantor’s Number</th>
<th>Federal Expenditures</th>
<th>Subrecipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Passed through Tufts University:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamins D and K Neuropathologically-Defined Alzheimer and Other Dementias in Older Persons</td>
<td>93.866</td>
<td>AG051641</td>
<td>171,963</td>
<td></td>
</tr>
<tr>
<td>Passed through Mt. Sinai:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peripheral and Brain Levels of Advanced Glycation End Products AGEs and Incident Alzheimers Disease and Neuropathy</td>
<td>93.866</td>
<td>R01AG053446</td>
<td>347,297</td>
<td></td>
</tr>
<tr>
<td>Integrative Network Modeling of Cognitive Resilience to Alzheimer’s Disease Leveraging Existing Aging Research Networks to Investigate TBI and AD/ADRD risk (LEARN TBI &amp; AD)</td>
<td>93.866</td>
<td>R01AG057907</td>
<td>38,551</td>
<td></td>
</tr>
<tr>
<td>Passed through University of Wisconsin:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FMR1 Premutation Phenytons in Population-Based and Clinically-Ascertained Samples</td>
<td>93.865</td>
<td>R01HD082110</td>
<td>26,713</td>
<td></td>
</tr>
<tr>
<td>Passed through Mclean Hospital:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human iPSC-based Personalized Cell Therapy of PD</td>
<td>93.853</td>
<td>R01NS070577</td>
<td>197,318</td>
<td></td>
</tr>
<tr>
<td>Passed through RITI:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assessing Preferences for use of Clinical Data Among Individuals with IDD and Their Guardians</td>
<td>93.310</td>
<td>R01HD086702</td>
<td>3,352</td>
<td></td>
</tr>
<tr>
<td>Decisional Capacity and Informed Consent in Fragile X Syndrome</td>
<td>93.865</td>
<td>R01HD071987</td>
<td>2,872</td>
<td></td>
</tr>
<tr>
<td>Passed through University of Kansas:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Effects of Parenting on the Development and Behavior of FXS Adolescents</td>
<td>93.865</td>
<td>R01HD084563</td>
<td>67,813</td>
<td></td>
</tr>
<tr>
<td>Passed through Thomas Jefferson:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Optimizing Ultrasound Enhanced Delivery of Therapeutics</td>
<td>93.394</td>
<td>R01CA199646</td>
<td>4,009</td>
<td></td>
</tr>
<tr>
<td>Passed through Beth Israel:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APOLLO - Upper Midwest</td>
<td>93.847</td>
<td>U01DK116092</td>
<td>31,752</td>
<td></td>
</tr>
<tr>
<td>Passed through Cleveland Clinic:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dementia with Lewy Bodies Consortium</td>
<td>93.853</td>
<td>U01NS060610</td>
<td>36,995</td>
<td></td>
</tr>
<tr>
<td>Passed through Cel-Sci Corporation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preclinical Studies of Pg70 Leaps Peptide Vaccines for Rheumatoid Arthritis</td>
<td>93.846</td>
<td>2R44AR063504</td>
<td>205,718</td>
<td></td>
</tr>
<tr>
<td>Passed through Intel Rett Syndrome FDN:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rett Syndrome, MECP2 Duplications, and Rett-related DisorderNatural History</td>
<td>93.865</td>
<td>2U54HD061222-11</td>
<td>39,474</td>
<td></td>
</tr>
<tr>
<td>Passed through the Jackson Laboratory:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systems Genetics Analysis of Resilience to Alzheimer’s Disease</td>
<td>93.866</td>
<td>R01AG057914</td>
<td>33,915</td>
<td></td>
</tr>
<tr>
<td>Passed through Medical College of South Carolina:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genetic Marker of IgG and CytomegalovirusImmune evasion in Alzheimer Disease</td>
<td>93.866</td>
<td>R21AG058489</td>
<td>28,133</td>
<td></td>
</tr>
<tr>
<td>Passed through National Fragile X Foundation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fragile X Clinic and Research Cooperative ConsortiumAgreement</td>
<td>93.315</td>
<td>U01DD001186</td>
<td>978</td>
<td></td>
</tr>
<tr>
<td>Passed through Valitor Inc:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long-acting anti-TNFa conjugates to minimize osteolysis around joint replacement devices</td>
<td>93.846</td>
<td>R43AR071857</td>
<td>20,971</td>
<td></td>
</tr>
<tr>
<td>Passed through Minneapolis Medical Research Foundation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin in Reducing Events in the Elderly (Aspree)</td>
<td>93.866</td>
<td>U01AG029824</td>
<td>49,456</td>
<td></td>
</tr>
<tr>
<td>Aspirin in reducing events in the elderly</td>
<td>93.866</td>
<td>U01AG029824</td>
<td>7,092</td>
<td></td>
</tr>
<tr>
<td>Total U.S. Department of Health and Human Services</td>
<td></td>
<td></td>
<td></td>
<td>73,776,294</td>
</tr>
<tr>
<td>Total U.S. Department of Agriculture:</td>
<td></td>
<td></td>
<td></td>
<td>11,338,239</td>
</tr>
<tr>
<td>Passed through Care Progress:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBIR Phase II: Leveraging Health Information Technology to Improve Communication between Cancer Patients and Providers</td>
<td>10.212</td>
<td>1534685</td>
<td>3,311</td>
<td></td>
</tr>
<tr>
<td>Total U.S. Department of Agriculture</td>
<td></td>
<td></td>
<td></td>
<td>3,311</td>
</tr>
<tr>
<td>U.S. Army Medical Research Acquisition Activity:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Targeting Prolyl Peptidases in Triple-Negative Breast Cancer</td>
<td>12.420</td>
<td>WB1XWH-16-1-0025</td>
<td>201,842</td>
<td></td>
</tr>
<tr>
<td>Objective Phenotyping in Cervical Dysplasia</td>
<td>12.420</td>
<td>WB1XWH-17-1-0394</td>
<td>222,705</td>
<td></td>
</tr>
<tr>
<td>Targeting Diet-Microbiome Interactions in the Pathogenesis of Parkinson’s Disease</td>
<td>12.420</td>
<td>WB1XWH-17-1-0587</td>
<td>73,148</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
### Rush System for Health

**Schedule of Expenditures of Federal Awards**

**Year Ended June 30, 2019**

<table>
<thead>
<tr>
<th>Federal Grantor/Pass-Through</th>
<th>Federal CFDA Number</th>
<th>Subrecipients</th>
<th>Federal Expenditures</th>
</tr>
</thead>
<tbody>
<tr>
<td>University of California:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Role of an Aggrecan 32mer Fragment in Post-Traumatic Osteoarthritis</td>
<td>12.420 W81XWH-16-1-0706</td>
<td>4,682</td>
<td></td>
</tr>
<tr>
<td>Total U.S. Army Medical Research Acquisition Activity</td>
<td></td>
<td>553,891</td>
<td>-</td>
</tr>
<tr>
<td>U.S. Department of Education:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Web-Based Assessment of Social-Emotional Learning in Grades Four to Six</td>
<td>84.305 R305A160053</td>
<td>323,881</td>
<td>26,743</td>
</tr>
<tr>
<td>VESPIT: Virtual Environment for Social information processing assessment tool for Upper Elementary and Middle School Students</td>
<td>84.305 R305A150189</td>
<td>351,504</td>
<td>28,942</td>
</tr>
<tr>
<td>Total Department of Education</td>
<td></td>
<td>675,386</td>
<td>55,685</td>
</tr>
</tbody>
</table>

**Total Research and Development**

- 75,008,882
- 11,393,924

### Student Financial Assistance

| U.S. Department of Education: | | | |
| Stafford Loan | 84.268 P268X5336 | 39,562,584 |
| Grad Plus | 84.268 P268X5336 | 14,675,386 |
| Parent Loans for Undergraduate Students | 84.268 P268X5336 | 42,489 |
| Perkins Loan | 84.038 P038A031271 | - |
| Perkins Loan-outstanding loan bal. at measurement date | 84.038 | 4,386,693 |
| Pell Grant Program | 84.063 P063P125336 | 279,281 |
| Supplemental Educational Opportunity Grant | 84.007 P007A121271 | 162,625 |
| Federal Work Study | 84.033 P033A121271 | 382,189 |
| Total U.S. Dept of Education | | 59,491,247 | - |

| U.S. Department of Health and Human Services: | | | |
| Loans for Disadvantaged Students-outstanding loan bal. at measurement date | 93.342 | 1,206,081 |
| Nursing Student Loan-Undergraduate-outstanding loan bal. at measurement date | 93.342 | 54,545 |
| Nursing Student Loan-Graduate-outstanding loan bal. at measurement date | 93.342 | 470,218 |
| Primary Care Loan/HPSL-outstanding loan bal. at measurement date | 93.342 | 1,641,862 |
| Nurse Faculty Loan Program-outstanding loan bal. at measurement date-ARRA | 93.408 | 190,334 |
| Nurse Faculty Loan Program-outstanding loan bal. at measurement date | 93.264 | 900,684 |
| Nursing Student Loan | 93.364 E4 DHP19180 | 90,002 |
| Nurse Faculty Loan Program | 93.264 E01 HP28838 | 131,287 |
| Total U.S. Department of Health and Human Services | | 4,685,013 | - |

**Total Student Financial Assistance**

- 64,176,260
- -

### Other Federal Assistance

| Passed through Washington State Department of Social and Health Services: | | | |
| Bridge Model | 93.048 9 DNW8C0004-01-00 | 5,249 |
| Passed through State of Illinois Department of Human Services: | | | |
| Opioid STR Program | 93.788 43XC03497 | 443,717 |
| City of Chicago Health Promotion Services | 93.043 68760 | 44,826 |
| Health and Wellness Program | 14.218 43922 | 6,289 |
| Health Promotion and Nutrition Program | 93.043 72269 | 6,030 |
| Passed through City of Chicago-Chicago Department of Public Health: | | | |
| Expanded HIV Testing for Disproportionately affected populations | 93.940 30597 | 60,000 |
| ASPR Hospital Preparedness Program Ebola Response Program | 93.817 32949 | 10,022 |
| Passed through State of Illinois Department of Public Health: | | | |
| Family Planning Program | 93.217 96180065G | 79,588 |
| School Based Health Center | 93.994 96380037G | 160,320 |
| Regional Perinatal Network | 93.994 86380007F | 272,930 |
| Total Other Federal Assistance | | 1,088,971 | - |

**Total Expenditures of Federal Awards**

- 140,274,113
- 11,393,924
# Rush System for Health

## Schedule of Expenditures of State Awards

### Year Ended June 30, 2019

<table>
<thead>
<tr>
<th>State Grantor/Pass-Through</th>
<th>Grantor/Program or Cluster Title</th>
<th>Grantor's Number</th>
<th>Expenditures</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PASSED THROUGH THE ILLINOIS DEPARTMENT OF PUBLIC HEALTH:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Genetic Counseling/Clinical Services</td>
<td>93788111G</td>
<td>$71,752</td>
</tr>
<tr>
<td></td>
<td>Regional Perinatal Network</td>
<td>86380007F</td>
<td>142,212</td>
</tr>
<tr>
<td></td>
<td>School Based Health Center</td>
<td>96380037G</td>
<td>154,960</td>
</tr>
<tr>
<td></td>
<td>Family Planning</td>
<td>96180065G</td>
<td>49,472</td>
</tr>
<tr>
<td></td>
<td>Sickle Cell Program</td>
<td>93788304G</td>
<td>19,516</td>
</tr>
<tr>
<td></td>
<td>ELC and HAI</td>
<td>82680003F</td>
<td>52,520</td>
</tr>
<tr>
<td></td>
<td><strong>Total Illinois Department of Public Health</strong></td>
<td></td>
<td><strong>490,432</strong></td>
</tr>
<tr>
<td><strong>PASSED THROUGH CITY OF CHICAGO - CHICAGO DEPARTMENT OF PUBLIC HEALTH:</strong></td>
<td>Community Breast Health Services</td>
<td>PO 57470</td>
<td>62,081</td>
</tr>
<tr>
<td></td>
<td><strong>Total City of Chicago - Chicago Department of Public Health</strong></td>
<td></td>
<td><strong>62,081</strong></td>
</tr>
<tr>
<td><strong>PASSED THROUGH THE ILLINOIS DEPARTMENT OF HUMAN SERVICES:</strong></td>
<td>Early Intervention Services</td>
<td>FCSX005147</td>
<td>2,876,299</td>
</tr>
<tr>
<td></td>
<td>Early Intervention Services</td>
<td>FCSX000924</td>
<td>726,208</td>
</tr>
<tr>
<td></td>
<td><strong>Total Illinois Department of Human Services</strong></td>
<td></td>
<td><strong>3,602,507</strong></td>
</tr>
<tr>
<td><strong>TOTAL EXPENDITURES OF STATE AWARDS</strong></td>
<td></td>
<td></td>
<td><strong>4,155,020</strong></td>
</tr>
<tr>
<td><strong>TOTAL EXPENDITURES FEDERAL AND STATE AWARDS</strong></td>
<td></td>
<td></td>
<td><strong>144,429,133</strong></td>
</tr>
</tbody>
</table>
RUSH SYSTEM FOR HEALTH

NOTES TO THE SCHEDULES OF EXPENDITURES OF FEDERAL AWARDS AND STATE AWARDS
FOR THE YEAR ENDED JUNE 30, 2019

1. BASIS OF PRESENTATION
The accompanying Schedules of Expenditures of Federal Awards and State Awards (the “Schedules”) include the federal and state grant activity of Rush System for Health (the “System” or “Rush”). The Schedules have been prepared on the accrual basis of accounting. The information in the Schedules is presented in accordance with the requirements of U.S. Office of Management and Budget Uniform Guidance, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Award.

2. SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES
Expenditures reported on the Schedules are presented on the accrual basis of accounting. Such expenditures are recognized following cost principles contained in OMB Uniform Guidance in 2 CFR Part 200 wherein certain types of expenditures are not allowable or are limited as to reimbursement. Pass-through entity identifying numbers are presented where available. Rush did not elect to utilize the de minimis indirect cost rate as allowed under Uniform Guidance.

3. LOANS WITH CONTINUING REQUIREMENTS
The outstanding balances as of June 30, 2019 for those loan programs for which the Federal Government imposes continuing compliance requirements are as follows:

<table>
<thead>
<tr>
<th>Loan Program</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perkins Loan</td>
<td>$4,386,693</td>
</tr>
<tr>
<td>Loans for Disadvantaged Students</td>
<td>929,371</td>
</tr>
<tr>
<td>Nursing Student Loan-Undergraduate</td>
<td>33,015</td>
</tr>
<tr>
<td>Nursing Student Loan-Graduate</td>
<td>439,728</td>
</tr>
<tr>
<td>Primary Care Loan/HPSL</td>
<td>1,263,216</td>
</tr>
<tr>
<td>Nurse Faculty Loan Program-ARRA</td>
<td>149,814</td>
</tr>
<tr>
<td>Nurse Faculty Loan Program</td>
<td>892,011</td>
</tr>
</tbody>
</table>

4. NONCASH ASSISTANCE
Rush did not receive any noncash federal awards or in-kind contributions during fiscal year 2019. In addition, Rush did not have any federal insurance in effect during the year ended June 30, 2019, to specifically cover federal expenditures.
RUSH SYSTEM FOR HEALTH

SCHEDULE OF FINDINGS AND QUESTIONED COSTS
FOR THE YEAR ENDED JUNE 30, 2019

Part I—Summary of Auditors’ Results

Financial Statements

Type of auditors’ report issued: unmodified Internal control over financial reporting:

- Material weakness(es) identified? _____ yes X no
- Significant deficiency(ies) identified that are not considered to be material weaknesses? _____ yes X none reported
- Noncompliance material to consolidated financial statements noted? _____ yes X no

Federal Awards

Internal control over major programs:

- Material weakness(es) identified? _____ yes X no
- Significant deficiency(ies) identified that are not considered to be material weakness(es)? _____ yes X none reported

Type of auditors’ report issued on compliance for major programs: unmodified

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516 of OMB Uniform Guidance? _____ yes X no

Identification of major programs:

<table>
<thead>
<tr>
<th>CFDA Numbers</th>
<th>Name of Federal Program or Cluster</th>
</tr>
</thead>
<tbody>
<tr>
<td>Various</td>
<td>Student Financial Aid</td>
</tr>
</tbody>
</table>

Dollar threshold used to distinguish between type A and type B programs: $3,000,000

Auditee qualified as low-risk auditee? _____ yes X no
RUSH SYSTEM FOR HEALTH

SCHEDULE OF FINDINGS AND QUESTIONED COSTS
FOR THE YEAR ENDED JUNE 30, 2019

Part II—Financial Statement Findings

None noted.

Part III—Federal Award Findings and Questioned Costs

None noted.
RUSH SYSTEM FOR HEALTH

SUMMARY SCHEDULE OF PRIOR AUDIT FINDINGS
FOR THE YEAR ENDED JUNE 30, 2019

Part II—Financial Statement Findings

None noted.

Part III—Federal Award Findings and Questioned Costs

None noted.